Any vaccine raised against any virus or viral derivative that causes hepatitis.
INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).
INFLAMMATION of the LIVER in humans caused by a member of the HEPATOVIRUS genus, HUMAN HEPATITIS A VIRUS. It can be transmitted through fecal contamination of food or water.
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
INFLAMMATION of the LIVER.
INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Any of the viruses that cause inflammation of the liver. They include both DNA and RNA viruses as well viruses from humans and animals.
Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
INFLAMMATION of the LIVER in animals due to viral infection.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Acute INFLAMMATION of the LIVER in humans; caused by HEPATITIS E VIRUS, a non-enveloped single-stranded RNA virus. Similar to HEPATITIS A, its incubation period is 15-60 days and is enterically transmitted, usually by fecal-oral transmission.
Two or more vaccines in a single dosage form.
Antibodies to the HEPATITIS A ANTIGENS including antibodies to envelope, core, and non-structural proteins.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
A positive-stranded RNA virus species in the genus HEPEVIRUS, causing enterically-transmitted non-A, non-B hepatitis (HEPATITIS E).
Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
A strain of HEPATITIS A VIRUS which causes hepatitis in humans. The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the fecal-oral route.
A genus of PICORNAVIRIDAE causing infectious hepatitis naturally in humans and experimentally in other primates. It is transmitted through fecal contamination of food or water. HEPATITIS A VIRUS is the type species.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.
INFLAMMATION of the LIVER in non-human animals.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.
A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES.
A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis B and chronic hepatitis. It requires the presence of a hepadnavirus for full replication. This is the lone species in the genus Deltavirus.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Pathological processes of the LIVER.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Tumors or cancer of the LIVER.
Disease having a short and relatively severe course.
A species of the CORONAVIRUS genus causing hepatitis in mice. Four strains have been identified as MHV 1, MHV 2, MHV 3, and MHV 4 (also known as MHV-JHM, which is neurotropic and causes disseminated encephalomyelitis with demyelination as well as focal liver necrosis).
Immunoglobulins produced in response to VIRAL ANTIGENS.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions.
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1.
Ribonucleic acid that makes up the genetic material of viruses.
INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
An ORTHOHEPADNAVIRUS causing chronic liver disease and hepatocellular carcinoma in woodchucks. It closely resembles the human hepatitis B virus.
Deoxyribonucleic acid that makes up the genetic material of viruses.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Antigens of the virions of HEPACIVIRUS, their surface, core, or other associated antigens.
Schedule giving optimum times usually for primary and/or secondary immunization.
A bile pigment that is a degradation product of HEME.
A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more.
A genus of Sciuridae consisting of 14 species. They are shortlegged, burrowing rodents which hibernate in winter.
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
The transference of a part of or an entire liver from one human or animal to another.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
Antigens produced by various strains of HEPATITIS A VIRUS such as the human hepatitis A virus (HEPATITIS A VIRUS, HUMAN).
The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.
Antigens from any of the hepatitis viruses including surface, core, and other associated antigens.
Antigens produced by various strains of HEPATITIS D VIRUS.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
The main structural component of the LIVER. They are specialized EPITHELIAL CELLS that are organized into interconnected plates called lobules.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A country in northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip, and the Red Sea north of Sudan, and includes the Asian Sinai Peninsula Its capital is Cairo.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
A DNA virus that closely resembles human hepatitis B virus. It has been recovered from naturally infected ducks.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
Proteins encoded by a VIRAL GENOME that are produced in the organisms they infect, but not packaged into the VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
Vaccines or candidate vaccines used to prevent ANTHRAX.
FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Proteins prepared by recombinant DNA technology.
Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
The common chimpanzee, a species of the genus Pan, family HOMINIDAE. It lives in Africa, primarily in the tropical rainforests. There are a number of recognized subspecies.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
Diagnostic procedures involving immunoglobulin reactions.
Elements of limited time intervals, contributing to particular results or situations.
Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)
Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID.
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
Substances elaborated by viruses that have antigenic activity.
Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.
Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.
The practice of medicine as applied to special circumstances associated with military operations.
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.
Therapy with two or more separate preparations given for a combined effect.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
Established cell cultures that have the potential to propagate indefinitely.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions.
The complete genetic complement contained in a DNA or RNA molecule in a virus.

Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. (1/271)

Hybrids of tobacco mosaic virus (TMV) were constructed with the use of fusion to the coat protein peptides of 10 or 15 amino acids, containing the 5B19 epitope from the spike protein of murine hepatitis virus (MHV) and giving rise to TMV-5B19 and TMV-5B19L, respectively. The TMV hybrids were propagated in tobacco plants, and the virus particles were purified. Immunogold labeling, with the use of the monoclonal MAb5B19 antibody, showed specific decoration of hybrid TMV particles, confirming the expression and display of the MHV epitope on the surface of the TMV. Mice were immunized with purified hybrid viruses after several regimens of immunization. Mice that received TMV-5B19L intranasally developed serum IgG and IgA specific for the 5B19 epitope and for the TMV coat protein. Hybrid TMV-5B19, administered by subcutaneous injections, elicited high titers of serum IgG that was specific for the 5B19 epitope and for coat protein, but IgA that was specific against 5B19 was not observed. Mice that were immunized with hybrid virus by subcutaneous or intranasal routes of administration survived challenge with a lethal dose (10 x LD50) of MHV strain JHM, whereas mice administered wild-type TMV died 10 d post challenge. Furthermore, there was a positive correlation between the dose of administered immunogen and protection against MHV infection. These studies show that TMV can be an effective vaccine delivery vehicle for parenteral and mucosal immunization and for protection from challenge with viral infection.  (+info)

Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. (2/271)

Interactive glycoproteins present on the surface of viral particles represent the main target of neutralizing antibodies. The ability of DNA vaccination to induce antibodies directed at such structures was investigated by using eight different expression plasmids engineered either to favor or to prevent interaction between the hepatitis C virus (HCV) envelope glycoproteins E1 and E2. Independently of the injection route (intramuscular or intraepidermal), plasmids expressing antigens capable of forming heterodimers presumed to be the prebudding form of the HCV envelope protein complex failed to induce any significant, stable antibodies following injection in mice. In sharp contrast, high titers of antibodies directed at both conformational and linear determinants were induced by using plasmids expressing severely truncated antigens that have lost the ability to form native complexes. In addition, only a truncated form of E2 induced antibodies reacting against the hypervariable region 1 of E2 (specifically with the C-terminal part of it) known to contain a neutralization site. When injected intraepidermally into small primates, the truncated E2-encoding plasmid induced antibodies able to neutralize in vitro the binding of a purified E2 protein onto susceptible cells. Because such antibodies have been associated with viral clearance in both humans and chimpanzees, these findings may have important implications for the development of protective immunity against HCV.  (+info)

Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). (3/271)

Routine vaccination of children is the most effective way to reduce hepatitis A incidence nationwide over time. Since licensure of hepatitis A vaccine in 1995, this strategy has been implemented incrementally, starting with the recommendation of the Advisory Committee on Immunization Practices (ACIP) in 1996 to vaccinate children living in communities with the highest rates of infection and disease. These updated recommendations represent the next phase of this hepatitis A immunization strategy. Vaccination of children living in states and communities with consistently elevated rates of hepatitis A will provide protection from disease and is expected to reduce the overall incidence of hepatitis A. This report updates the ACIP's 1996 recommendations on the prevention of hepatitis A through immunization (MMWR 1996;45:[No. RR-151) and includes a) new data about the epidemiology of hepatitis A; b) recent findings about the effectiveness of community-based hepatitis A vaccination programs; and c) recommendations for the routine vaccination of children in states, counties, and communities with rates that are twice the 1987-1997 national average or greater (i.e., > or = 20 cases per 100,000 population) and consideration of routine vaccination of children in states, counties, and communities with rates exceeding the 1987-1997 national average (i.e., > or = 10 but <20 cases per 100,000 population). Unchanged in this report are previous recommendations regarding the vaccination of persons in groups at increased risk for hepatitis A or its adverse consequences and recommendations regarding the use of immune globulin for protection against hepatitis A.  (+info)

Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. (4/271)

Organ transplant recipients with chronic hepatitis B or hepatitis C virus infection may be at increased risk of fulminant hepatitis A. Liver transplant (LTX) recipients, renal transplant (RTX) recipients, and healthy controls received 2 doses of hepatitis A vaccine 6 months apart. Anti-hepatitis A virus (anti-HAV) seroconversion after the primary dose occurred in 41% of the LTX patients, 24% of the RTX patients, and 90% of the controls. After the booster dose, the respective rates were 97%, 72%, and 100% (P<.001). RTX patients also had significantly lower geometric mean titers (GMTs) of anti-HAV than LTX patients and controls. In the RTX group, the seroconversion rate and GMT were inversely associated with the number of immunosuppressive drugs received by the patients. The vaccine was well tolerated. Hepatitis A vaccine can be recommended to LTX and RTX patients, but the patients should receive a full course of 2 doses before imminent exposure.  (+info)

Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. (5/271)

A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers >/=11 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference.  (+info)

Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. (6/271)

BACKGROUND: Hepatitis B (HBV)-infected patients have a higher morbidity and mortality when super-infected by hepatitis A (HAV). AIM: To evaluate the immunogenicity and safety of a commercial inactivated HAV vaccine in Chinese patients with chronic HBV infection. METHODS: Sixty-five HBV-infected patients (30 carriers, 22 chronic hepatitis, 13 cirrhosis), who were seronegative for HAV, received a dose of 1440 ELISA units of HAV vaccine at weeks 0 and 24. Twenty-eight healthy individuals aged 18-57 years, who were seronegative for both HBV and HAV infection, also received the same vaccination regimen. Seroconversion was defined as an anti-HAV titre >/= 33 mIU/mL. RESULTS: The seroconversion rates for the HBV-infected patients at weeks 2, 4 and 24 were 72, 91 and 80%, respectively. The corresponding geometric mean titres (GMTs) were 103, 311 and 123 mIU/mL. In the healthy control group the seroconversion rates were 86, 93 and 89% at weeks 2, 4 and 24. The corresponding GMTs were 112, 158 and 250 mIU/mL. There was no difference in the seroconversion rates between the two groups, but healthy controls had a significantly higher GMT at week 24 (P=0.04). Side-effects were more common in HBV patients. CONCLUSION: The HAV vaccine is equally efficacious in patients with chronic HBV infection.  (+info)

Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. (7/271)

DNA-based immunizations have been used to elicit cellular immunity to hepatitis C virus (HCV) proteins in mice. Mice were immunized by intramuscular or intradermal injections of plasmid DNA derived from a near-full-length HCV genotype 1b genomic clone (pRC/B2) or individual genomic clones. These immunizations induced cytotoxic T lymphocytes (CTLs), as revealed in standard chromium-release assays that used syngeneic peptide-pulsed or transfected target cells. These assays identified four CTL epitopes within the capsid, E1, and E2 regions of the polyprotein sequence of HCV genotype 1a that were cross-reactive with HCV genotype 1b. Additionally, CTLs derived from mice immunized with either NS3 or NS5 specifically lysed target cells sensitized to either the genotype 1a or 1b gene products. Nucleic acid immunizations also generated humoral immunity to HCV proteins, as detected by anti-HCV reactivity to NS3 and capsid in ELISAs and immunoblot assays.  (+info)

Prevalence of hepatitis B, D and C virus infections among children and pregnant women in Moldova: additional evidence supporting the need for routine hepatitis B vaccination of infants. (8/271)

Rates of acute hepatitis B are high in Moldova, but the prevalence of chronic infection is unknown. In 1994, we surveyed children and pregnant women, collected demographic information, and drew blood for laboratory testing. Among the 439 children (mean age, 5 years), the prevalence of antibody to hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) were 17.1 and 6.8%, respectively. Among the 1098 pregnant women (mean age, 26 years), 52.4% were anti-HBc-positive and 9.7% were HBsAg-positive. Of the HBsAg-positive pregnant women, 35.6% were hepatitis B e antigen (HBeAg) positive and 18.3% had antibodies to hepatitis D virus. The prevalence of antibody to hepatitis C virus was 1.4% in children and 2.3% in pregnant women. The high HBeAg prevalence among HBsAg-positive pregnant women and the high anti-HBc prevalence among children indicate that both perinatal and early childhood transmission contribute to the high hepatitis B virus endemicity in Moldova.  (+info)

Note: This definition may have some variations in different contexts and medical fields.

Hepatitis A is typically spread through contaminated food and water or through close contact with someone who has the infection. The virus can also be spread through sexual contact or sharing of needles.

Symptoms of hepatitis A usually appear two to six weeks after exposure and can last for several weeks or months. In some cases, the infection can lead to complications such as liver failure, which can be life-threatening.

There is a vaccine available for hepatitis A, which is recommended for individuals traveling to areas where the virus is common, people who engage in high-risk behaviors, and those with chronic liver disease. Treatment for hepatitis A typically focuses on relieving symptoms and supporting the liver as it recovers. In severe cases, hospitalization may be necessary.

Preventive measures to reduce the risk of hepatitis A infection include maintaining good hygiene practices, such as washing hands frequently, especially before eating or preparing food; avoiding consumption of raw or undercooked shellfish, particularly oysters; and avoiding close contact with people who have the infection.

The symptoms of hepatitis B can range from mild to severe and may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, joint pain, and jaundice (yellowing of the skin and eyes). In some cases, hepatitis B can be asymptomatic, meaning that individuals may not experience any symptoms at all.

Hepatitis B is diagnosed through blood tests that detect the presence of HBV antigens or antibodies in the body. Treatment for acute hepatitis B typically involves rest, hydration, and medication to manage symptoms, while chronic hepatitis B may require ongoing therapy with antiviral drugs to suppress the virus and prevent liver damage.

Preventive measures for hepatitis B include vaccination, which is recommended for individuals at high risk of infection, such as healthcare workers, sexually active individuals, and those traveling to areas where HBV is common. In addition, safe sex practices, avoiding sharing of needles or other bodily fluids, and proper sterilization of medical equipment can help reduce the risk of transmission.

Overall, hepatitis B is a serious infection that can have long-term consequences for liver health, and it is important to take preventive measures and seek medical attention if symptoms persist or worsen over time.

There are several types of hepatitis C, including genotype 1, which is the most common and accounts for approximately 70% of cases in the United States. Other genotypes include 2, 3, 4, 5, and 6. The symptoms of hepatitis C can range from mild to severe and may include fatigue, fever, loss of appetite, nausea, vomiting, joint pain, jaundice (yellowing of the skin and eyes), dark urine, pale stools, and itching all over the body. Some people with hepatitis C may not experience any symptoms at all.

Hepatitis C is diagnosed through a combination of blood tests that detect the presence of antibodies against HCV or the virus itself. Treatment typically involves a combination of medications, including interferon and ribavirin, which can cure the infection but may have side effects such as fatigue, nausea, and depression. In recent years, new drugs known as direct-acting antivirals (DAAs) have become available, which can cure the infection with fewer side effects and in a shorter period of time.

Prevention measures for hepatitis C include avoiding sharing needles or other drug paraphernalia, using condoms to prevent sexual transmission, and ensuring that any tattoos or piercings are performed with sterilized equipment. Vaccines are also available for people who are at high risk of contracting the virus, such as healthcare workers and individuals who engage in high-risk behaviors.

Overall, hepatitis C is a serious and common liver disease that can lead to significant health complications if left untreated. Fortunately, with advances in medical technology and treatment options, it is possible to manage and cure the virus with proper care and attention.

A persistent infection with the hepatitis B virus (HBV) that can lead to liver cirrhosis and hepatocellular carcinoma. HBV is a bloodborne pathogen and can be spread through contact with infected blood, sexual contact, or vertical transmission from mother to child during childbirth.

Chronic hepatitis B is characterized by the presence of HBsAg in the blood for more than 6 months, indicating that the virus is still present in the liver. The disease can be asymptomatic or symptomatic, with symptoms such as fatigue, malaise, loss of appetite, nausea, vomiting, joint pain, and jaundice.

Chronic hepatitis B is diagnosed through serological tests such as HBsAg, anti-HBc, and HBV DNA. Treatment options include interferon alpha and nucleos(t)ide analogues, which can slow the progression of the disease but do not cure it.

Prevention strategies for chronic hepatitis B include vaccination with hepatitis B vaccine, which is effective in preventing acute and chronic HBV infection, as well as avoidance of risky behaviors such as unprotected sex and sharing of needles.

The symptoms of chronic hepatitis C may be mild or absent, but some people experience fatigue, joint pain, muscle aches, nausea, loss of appetite, and jaundice (yellowing of the skin and eyes).

Chronic hepatitis C is usually diagnosed through blood tests that detect the presence of antibodies against HCV or the virus itself. Imaging tests such as ultrasound and liver biopsy may also be performed to assess the extent of liver damage.

Treatment for chronic hepatitis C typically involves a combination of medications, including interferon and ribavirin, which can help clear the virus from the body. In severe cases, a liver transplant may be necessary. Prevention of the spread of HCV includes avoiding sharing of needles or other sharp objects, practicing safe sex, and getting tested for the virus before donating blood or organs.

See also: Hepatitis C; Liver; Virus

There are several types of hepatitis, including:

1. Hepatitis A: This type is caused by the hepatitis A virus (HAV) and is usually transmitted through contaminated food or water or through close contact with someone who has the infection.
2. Hepatitis B: This type is caused by the hepatitis B virus (HBV) and can be spread through sexual contact, sharing of needles, or mother-to-child transmission during childbirth.
3. Hepatitis C: This type is caused by the hepatitis C virus (HCV) and is primarily spread through blood-to-blood contact, such as sharing of needles or receiving a tainted blood transfusion.
4. Alcoholic hepatitis: This type is caused by excessive alcohol consumption and can lead to inflammation and scarring in the liver.
5. Drug-induced hepatitis: This type is caused by certain medications, such as antidepressants, anti-seizure drugs, or chemotherapy agents.
6. Autoimmune hepatitis: This type is caused by an abnormal immune response and can lead to inflammation in the liver.

Symptoms of hepatitis may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, and yellowing of the skin (jaundice). In severe cases, it can lead to liver failure or even death.

Diagnosis of hepatitis is typically made through a combination of physical examination, laboratory tests such as blood tests and imaging studies like ultrasound or CT scans. Treatment options vary depending on the cause and severity of the condition, but may include medications to manage symptoms, antiviral therapy, or in severe cases, liver transplantation. Prevention measures for hepatitis include vaccination against certain types of the disease, practicing safe sex, avoiding sharing needles or other drug paraphernalia, and following proper hygiene practices.

In conclusion, hepatitis is a serious condition that affects millions of people worldwide. It is important to be aware of the different types of hepatitis and their causes in order to prevent and manage this condition effectively. By taking appropriate measures such as getting vaccinated and practicing safe sex, individuals can reduce their risk of contracting hepatitis. In severe cases, early diagnosis and treatment can help to minimize damage to the liver and improve outcomes for patients.

Hepatitis, chronic is a type of liver disease that is characterized by inflammation and damage to the liver, which can lead to scarring, cirrhosis, and potentially liver failure. It is caused by a variety of factors, including viral infections (such as hepatitis B and C), alcohol consumption, and autoimmune disorders.

Chronic hepatitis can be challenging to diagnose, as its symptoms are often nonspecific and may resemble those of other conditions. However, some common signs and symptoms include:

* Fatigue
* Loss of appetite
* Nausea and vomiting
* Abdominal pain
* Yellowing of the skin and eyes (jaundice)
* Dark urine
* Pale stools

If left untreated, chronic hepatitis can lead to serious complications, such as liver failure, liver cancer, and esophageal varices. Treatment options for chronic hepatitis depend on the underlying cause and may include medications, lifestyle changes, and in severe cases, liver transplantation.

Preventing Chronic Hepatitis:

While some forms of chronic hepatitis are incurable, there are steps you can take to prevent the development of this condition or slow its progression. These include:

* Avoiding alcohol or drinking in moderation
* Maintaining a healthy diet and lifestyle
* Getting vaccinated against hepatitis A and B
* Practicing safe sex to avoid sexually transmitted infections (STIs)
* Avoiding sharing needles or other drug-injecting equipment
* Seeking medical attention if you suspect you have been exposed to hepatitis

Managing Chronic Hepatitis:

If you have chronic hepatitis, managing the condition is crucial to prevent complications and improve quality of life. This may involve:

* Medications to treat the underlying cause of the hepatitis (e.g., antiviral drugs for hepatitis B or C)
* Lifestyle changes, such as avoiding alcohol and maintaining a healthy diet
* Regular monitoring of liver function and viral load
* In some cases, liver transplantation

Living with Chronic Hepatitis:

Living with chronic hepatitis can be challenging, but there are resources available to help you cope. These may include:

* Support groups for people with hepatitis and their families
* Counseling to address emotional and mental health concerns
* Educational resources to help you understand the condition and its management
* Legal assistance to navigate insurance and disability benefits

Conclusion:

Chronic hepatitis is a complex and multifactorial condition that can have serious consequences if left untreated. However, with early diagnosis, appropriate treatment, and lifestyle changes, it is possible to manage the condition and improve quality of life. By understanding the causes, symptoms, diagnosis, and management of chronic hepatitis, you can take an active role in your healthcare and make informed decisions about your care.

A viral infection that affects the liver and is transmitted to animals through contact with infected feces, urine, or saliva. The condition can be caused by several different viruses, including hepatitis A, B, C, D, and E. Symptoms of animal hepatitis may include loss of appetite, vomiting, diarrhea, lethargy, fever, and jaundice (yellowing of the skin and eyes). In severe cases, the infection can cause liver failure and death.

Prevention:

* Avoid contact with infected animals
* Practice good hygiene, such as washing hands frequently
* Keep pets up to date on vaccinations and preventatives
* Avoid drinking water or eating food that may be contaminated with feces or urine from infected animals
* Use protective clothing and equipment when handling animals that may be infected

Treatment:

* Supportive care, such as fluids and electrolytes to prevent dehydration and maintain blood pressure
* Antiviral medications in severe cases
* Hospitalization for severe cases or those that do not respond to treatment

Prognosis:

* Depends on the severity of the infection and the underlying health status of the animal. In general, the prognosis is good for animals that receive prompt and appropriate treatment.

Complications:

* Liver failure
* Sepsis (blood infection)
* Kidney failure
* Death

Prevalence:

* Widespread in animals, especially in those that are kept in close quarters or have poor living conditions.

Affected Organ:

* Liver

Symptoms of hepatitis E can include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, and yellowing of the skin and eyes (jaundice).

Hepatitis E is usually a self-limiting disease, meaning it will resolve on its own without treatment. However, in some cases, it can lead to fulminant hepatitis, which is a severe and potentially life-threatening form of liver disease.

There are several ways to diagnose hepatitis E, including blood tests to detect the presence of HEV antigens or antibodies, as well as imaging tests such as ultrasound or CT scans to evaluate liver function.

Treatment for hepatitis E is typically supportive, meaning it focuses on managing symptoms and maintaining hydration. In severe cases, hospitalization may be necessary to monitor and treat complications. Prevention of hepatitis E involves improving access to safe water and sanitation, as well as promoting good hygiene practices, such as washing hands regularly.

Vaccines are available for hepatitis E, but they are not widely available or recommended for most individuals. However, they may be recommended for certain high-risk groups, such as people living in areas with a high prevalence of HEV infection or those traveling to such areas.

The hepatitis D virus is transmitted through contact with infected blood or through sexual contact with an infected person. It can also be spread from mother to child during pregnancy or childbirth. Hepatitis D is a critical illness, and it can lead to liver failure, especially in people who are already infected with HBV.

There are two main types of hepatitis D: acute and chronic. Acute hepatitis D lasts for less than six months and typically resolves on its own without treatment. Chronic hepatitis D, on the other hand, can last for more than six months and can cause long-term liver damage.

Treatment for hepatitis D usually involves a combination of medications to manage symptoms and reduce inflammation in the liver. In severe cases, a liver transplant may be necessary. Prevention methods for hepatitis D include getting vaccinated against HBV, practicing safe sex, and avoiding sharing needles or other drug equipment.

Hepatitis D is a serious condition that can lead to complications such as liver failure, so it is important to seek medical attention if symptoms persist or worsen over time.

The condition can be caused by a variety of factors, including excessive alcohol consumption, viral hepatitis, non-alcoholic fatty liver disease, and certain medications. It can also be a complication of other diseases such as hemochromatosis and Wilson's disease.

The symptoms of liver cirrhosis can vary depending on the severity of the disease, but may include fatigue, loss of appetite, nausea, abdominal swelling, and pain in the upper right side of the abdomen. As the disease progresses, it can lead to complications such as esophageal varices, ascites, and liver failure, which can be life-threatening.

There is no cure for liver cirrhosis, but treatment options are available to manage the symptoms and slow the progression of the disease. These may include medications to control swelling and pain, dietary changes, and in severe cases, liver transplantation. In some cases, a liver transplant may be necessary if the disease has caused significant damage and there is no other option to save the patient's life.

In conclusion, liver cirrhosis is a serious and potentially life-threatening condition that can cause significant damage to the liver and lead to complications such as liver failure. It is important for individuals to be aware of the risk factors and symptoms of the disease in order to seek medical attention if they suspect they may have liver cirrhosis. With proper treatment and management, it is possible to slow the progression of the disease and improve the patient's quality of life.

In animals, hepatitis can be caused by a variety of agents, including:

1. Viral hepatitis: Caused by viruses such as feline infectious peritonitis (FIP) in cats and canine infectious hepatitis (CIH) in dogs.
2. Bacterial hepatitis: Caused by bacteria such as Leptospira spp., which can be transmitted through contact with contaminated water or soil.
3. Parasitic hepatitis: Caused by parasites such as liver flukes (Fasciola spp.) and tapeworms (Taenia spp.).
4. Toxic hepatitis: Caused by exposure to certain drugs, chemicals, or environmental toxins.
5. Genetic hepatitis: Caused by inherited genetic disorders such as hemophilia in dogs and cats.

The clinical signs of animal hepatitis can vary depending on the cause and severity of the disease, but may include lethargy, loss of appetite, vomiting, diarrhea, abdominal pain, and jaundice (yellowing of the skin and eyes). Diagnosis is based on a combination of physical examination, laboratory tests (such as blood tests and liver biopsy), and imaging studies.

Treatment of animal hepatitis depends on the underlying cause and may include supportive care, antibiotics, anti-inflammatory medications, and in some cases, surgery or liver transplantation. In severe cases, animal hepatitis can be fatal if left untreated, so early diagnosis and aggressive treatment are essential for a successful outcome.

Jaundice is typically diagnosed through physical examination and laboratory tests such as blood tests to measure bilirubin levels. Treatment depends on the underlying cause, but may include medications to reduce bilirubin production or increase its excretion, or surgery to remove blockages in the bile ducts.

Here are some of the synonyms for Jaundice:

1. Yellow fever
2. Yellow jaundice
3. Hepatitis
4. Gallstones
5. Cholestasis
6. Obstruction of the bile ducts
7. Biliary tract disease
8. Hemochromatosis
9. Sickle cell anemia
10. Crigler-Najjar syndrome

Here are some of the antonyms for Jaundice:

1. Pinkness
2. Normal skin color
3. Healthy liver function
4. Bilirubin levels within normal range
5. No signs of liver disease or obstruction of bile ducts.

The exact cause of autoimmune hepatitis is not fully understood, but it is believed to involve a combination of genetic and environmental factors. The condition can occur in people of all ages, although it is most common in women between the ages of 20 and 40.

Symptoms of autoimmune hepatitis may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, and yellowing of the skin and eyes (jaundice). If left untreated, the condition can lead to liver failure and even death.

Treatment for autoimmune hepatitis typically involves medications to suppress the immune system and reduce inflammation in the liver. In severe cases, a liver transplant may be necessary. Early diagnosis and treatment can improve the chances of a successful outcome.

There are many different types of liver diseases, including:

1. Alcoholic liver disease (ALD): A condition caused by excessive alcohol consumption that can lead to inflammation, scarring, and cirrhosis.
2. Viral hepatitis: Hepatitis A, B, and C are viral infections that can cause inflammation and damage to the liver.
3. Non-alcoholic fatty liver disease (NAFLD): A condition where there is an accumulation of fat in the liver, which can lead to inflammation and scarring.
4. Cirrhosis: A condition where the liver becomes scarred and cannot function properly.
5. Hemochromatosis: A genetic disorder that causes the body to absorb too much iron, which can damage the liver and other organs.
6. Wilson's disease: A rare genetic disorder that causes copper to accumulate in the liver and brain, leading to damage and scarring.
7. Liver cancer (hepatocellular carcinoma): Cancer that develops in the liver, often as a result of cirrhosis or viral hepatitis.

Symptoms of liver disease can include fatigue, loss of appetite, nausea, abdominal pain, dark urine, pale stools, and swelling in the legs. Treatment options for liver disease depend on the underlying cause and may include lifestyle changes, medication, or surgery. In severe cases, a liver transplant may be necessary.

Prevention of liver disease includes maintaining a healthy diet and lifestyle, avoiding excessive alcohol consumption, getting vaccinated against hepatitis A and B, and managing underlying medical conditions such as obesity and diabetes. Early detection and treatment of liver disease can help to prevent long-term damage and improve outcomes for patients.

There are several risk factors for developing HCC, including:

* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity

HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:

* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss

If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:

* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope

Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:

* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer

Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.

Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.

There are several types of liver neoplasms, including:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.

The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.

Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.

Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.

Examples of acute diseases include:

1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.

Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.

Hepatitis, Alcoholic: A type of hepatitis (inflammation of the liver) caused by excessive alcohol consumption over a long period of time. It is characterized by fatty degeneration of liver cells, inflammation, and fibrosis (scarring). The condition can progress to cirrhosis if left untreated.

The term "alcoholic hepatitis" does not refer only to alcohol-related liver disease but also includes other conditions such as fatty liver disease caused by excessive alcohol consumption.

Causes: The exact cause of alcoholic hepatitis is not fully understood, but it is believed that long-term heavy drinking can damage liver cells and lead to inflammation.

Symptoms: Symptoms of alcoholic hepatitis can range from mild to severe and include fatigue, loss of appetite, nausea, vomiting, abdominal pain, fever, and jaundice (yellowing of the skin and eyes).

Diagnosis: Diagnosis is based on a combination of physical examination, medical history, laboratory tests, and imaging studies such as ultrasound or CT scans.

Treatment: Treatment for alcoholic hepatitis typically involves stopping drinking altogether, nutritional support, and medication to manage symptoms. In severe cases, hospitalization may be necessary to monitor and treat complications.

Prevention: Preventing alcoholic hepatitis involves avoiding excessive alcohol consumption and seeking medical attention if symptoms persist or worsen over time.

Prognosis: The prognosis for alcoholic hepatitis depends on the severity of the condition and how well the individual responds to treatment. In severe cases, liver transplantation may be necessary.

This condition is most commonly seen in people with advanced liver disease, such as cirrhosis or liver cancer. It can also be caused by other conditions that affect the liver, such as hepatitis or portal hypertension.

Symptoms of hepatic encephalopathy can include confusion, disorientation, slurred speech, memory loss, and difficulty with coordination and balance. In severe cases, it can lead to coma or even death.

Diagnosis of hepatic encephalopathy is typically made through a combination of physical examination, medical history, and diagnostic tests such as blood tests and imaging studies. Treatment options include medications to reduce the production of ammonia in the gut, antibiotics to treat any underlying infections, and transjugular intrahepatic portosystemic shunt (TIPS) to improve liver function. In severe cases, a liver transplant may be necessary.

Overall, hepatic encephalopathy is a serious condition that can have significant impact on quality of life and survival in people with advanced liver disease. Early detection and prompt treatment are essential to prevent complications and improve outcomes.

Chronic hepatitis D can cause inflammation and damage to the liver, leading to scarring and cirrhosis. It can also increase the risk of developing liver cancer. Treatment options for chronic hepatitis D are limited and may include antiviral medications, pegylated interferon, and liver transplantation in severe cases.

Prevention of chronic hepatitis D primarily involves avoiding exposure to HBV, which is the primary risk factor for HDV infection. This can be achieved through vaccination against HBV, safe sex practices, and avoiding sharing of needles or other injection equipment.

Causes:

1. Viral hepatitis (hepatitis A, B, or C)
2. Overdose of medications or supplements
3. Toxic substances (e.g., alcohol, drugs, or chemicals)
4. Sepsis or other infections that spread to the liver
5. Certain autoimmune disorders (e.g., hemochromatosis, Wilson's disease)
6. Cancer that has metastasized to the liver
7. Blood vessel blockage or clotting in the liver
8. Lack of blood flow to the liver

Symptoms:

1. Jaundice (yellowing of skin and eyes)
2. Nausea and vomiting
3. Abdominal swelling and discomfort
4. Fatigue, weakness, and loss of appetite
5. Confusion or altered mental state
6. Seizures or coma
7. Pale or clay-colored stools
8. Dark urine

Diagnosis:

1. Physical examination and medical history
2. Laboratory tests (e.g., liver function tests, blood tests, imaging studies)
3. Biopsy of the liver tissue (to rule out other liver diseases)

Treatment:

1. Supportive care (fluids, nutrition, and medication to manage symptoms)
2. Addressing underlying causes (e.g., stopping alcohol or drug use, treating infections)
3. Transjugular intrahepatic portosystemic shunt (TIPS), a procedure that creates a new pathway for blood to flow through the liver
4. Liver transplantation (in severe cases where other treatments have failed)

Prognosis:
The prognosis for acute liver failure depends on the underlying cause of the condition and the severity of the liver damage. In general, the earlier the diagnosis and treatment, the better the outcome. However, acute liver failure can be a life-threatening condition, and the mortality rate is high, especially in cases where there is severe liver damage or no available donor liver for transplantation.

The definition of DILI has been revised several times over the years, but the most recent definition was published in 2013 by the International Consortium for DILI Research (ICDCR). According to this definition, DILI is defined as:

"A clinically significant alteration in liver function that is caused by a medication or other exogenous substance, and is not related to underlying liver disease. The alteration may be biochemical, morphological, or both, and may be acute or chronic."

The ICDCR definition includes several key features of DILI, including:

1. Clinically significant alteration in liver function: This means that the liver damage must be severe enough to cause symptoms or signs of liver dysfunction, such as jaundice, nausea, vomiting, or abdominal pain.
2. Caused by a medication or other exogenous substance: DILI is triggered by exposure to certain drugs or substances that are not related to underlying liver disease.
3. Not related to underlying liver disease: This means that the liver damage must not be caused by an underlying condition such as hepatitis B or C, alcoholic liver disease, or other genetic or metabolic disorders.
4. May be acute or chronic: DILI can occur as a sudden and severe injury (acute DILI) or as a slower and more insidious process (chronic DILI).

The ICDCR definition provides a standardized way of defining and diagnosing DILI, which is important for clinicians and researchers to better understand the cause of liver damage in patients who are taking medications. It also helps to identify the drugs or substances that are most likely to cause liver injury and to develop strategies for preventing or treating DILI.

HIV (human immunodeficiency virus) infection is a condition in which the body is infected with HIV, a type of retrovirus that attacks the body's immune system. HIV infection can lead to AIDS (acquired immunodeficiency syndrome), a condition in which the immune system is severely damaged and the body is unable to fight off infections and diseases.

There are several ways that HIV can be transmitted, including:

1. Sexual contact with an infected person
2. Sharing of needles or other drug paraphernalia with an infected person
3. Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Blood transfusions ( although this is rare in developed countries due to screening processes)
5. Organ transplantation (again, rare)

The symptoms of HIV infection can be mild at first and may not appear until several years after infection. These symptoms can include:

1. Fever
2. Fatigue
3. Swollen glands in the neck, armpits, and groin
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss

If left untreated, HIV infection can progress to AIDS, which is a life-threatening condition that can cause a wide range of symptoms, including:

1. Opportunistic infections (such as pneumocystis pneumonia)
2. Cancer (such as Kaposi's sarcoma)
3. Wasting syndrome
4. Neurological problems (such as dementia and seizures)

HIV infection is diagnosed through a combination of blood tests and physical examination. Treatment typically involves antiretroviral therapy (ART), which is a combination of medications that work together to suppress the virus and slow the progression of the disease.

Prevention methods for HIV infection include:

1. Safe sex practices, such as using condoms and dental dams
2. Avoiding sharing needles or other drug-injecting equipment
3. Avoiding mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Post-exposure prophylaxis (PEP), which is a short-term treatment that can prevent infection after potential exposure to the virus
5. Pre-exposure prophylaxis (PrEP), which is a daily medication that can prevent infection in people who are at high risk of being exposed to the virus.

It's important to note that HIV infection is manageable with proper treatment and care, and that people living with HIV can lead long and healthy lives. However, it's important to be aware of the risks and take steps to prevent transmission.

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.

What is a Chronic Disease?

A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:

1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke

Impact of Chronic Diseases

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.

Addressing Chronic Diseases

Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:

1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.

Conclusion

Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.

The term "alcoholic" in this context refers to the fact that the damage is caused by excessive alcohol consumption, rather than any other underlying medical condition or disease process. The suffix "-osis" means "condition" or "disease," and "alcoholic" modifies the noun "liver cirrhosis" to indicate the cause of the condition.

The term "LC-ALD" is used in medical literature and research to specifically refer to this type of cirrhosis caused by alcohol consumption, as opposed to other types of cirrhosis that may be caused by viral hepatitis or other factors.

There are several causes of liver failure, including:

1. Alcohol-related liver disease: Prolonged and excessive alcohol consumption can damage liver cells, leading to inflammation, scarring, and eventually liver failure.
2. Viral hepatitis: Hepatitis A, B, and C are viral infections that can cause inflammation and damage to the liver, leading to liver failure.
3. Non-alcoholic fatty liver disease (NAFLD): A condition where there is an accumulation of fat in the liver, leading to inflammation and scarring.
4. Drug-induced liver injury: Certain medications can cause liver damage and failure, especially when taken in high doses or for extended periods.
5. Genetic disorders: Certain inherited conditions, such as hemochromatosis and Wilson's disease, can cause liver damage and failure.
6. Acute liver failure: This is a sudden and severe loss of liver function, often caused by medication overdose or other toxins.
7. Chronic liver failure: A gradual decline in liver function over time, often caused by cirrhosis or NAFLD.

Symptoms of liver failure can include:

1. Jaundice (yellowing of the skin and eyes)
2. Fatigue
3. Loss of appetite
4. Nausea and vomiting
5. Abdominal pain
6. Confusion and altered mental state
7. Easy bruising and bleeding

Diagnosis of liver failure is typically made through a combination of physical examination, medical history, and laboratory tests, such as blood tests to check for liver enzymes and bilirubin levels. Imaging tests, such as ultrasound and CT scans, may also be used to evaluate the liver.

Treatment of liver failure depends on the underlying cause and severity of the condition. In some cases, a liver transplant may be necessary. Other treatments may include medications to manage symptoms, such as nausea and pain, and supportive care to maintain nutrition and hydration. In severe cases, hospitalization may be required to monitor and treat complications.

Prevention of liver failure is important, and this can be achieved by:

1. Avoiding alcohol or drinking in moderation
2. Maintaining a healthy weight and diet
3. Managing underlying medical conditions, such as diabetes and high blood pressure
4. Avoiding exposure to toxins, such as certain medications and environmental chemicals
5. Getting vaccinated against hepatitis A and B
6. Practicing safe sex to prevent the spread of hepatitis B and C.

There are two main types of fatty liver disease:

1. Alcoholic fatty liver disease (AFLD): This type of fatty liver disease is caused by excessive alcohol consumption and is the most common cause of fatty liver disease in the United States.
2. Non-alcoholic fatty liver disease (NAFLD): This type of fatty liver disease is not caused by alcohol consumption and is the most common cause of fatty liver disease worldwide. It is often associated with obesity, diabetes, and high cholesterol.

There are several risk factors for developing fatty liver disease, including:

* Obesity
* Physical inactivity
* High calorie intake
* Alcohol consumption
* Diabetes
* High cholesterol
* High triglycerides
* History of liver disease

Symptoms of fatty liver disease can include:

* Fatigue
* Abdominal discomfort
* Loss of appetite
* Nausea and vomiting
* Abnormal liver function tests

Diagnosis of fatty liver disease is typically made through a combination of physical examination, medical history, and diagnostic tests such as:

* Liver biopsy
* Imaging studies (ultrasound, CT or MRI scans)
* Blood tests (lipid profile, glucose, insulin, and liver function tests)

Treatment of fatty liver disease depends on the underlying cause and severity of the condition. Lifestyle modifications such as weight loss, exercise, and a healthy diet can help improve the condition. In severe cases, medications such as antioxidants, fibric acids, and anti-inflammatory drugs may be prescribed. In some cases, surgery or other procedures may be necessary.

Prevention of fatty liver disease includes:

* Maintaining a healthy weight
* Eating a balanced diet low in sugar and saturated fats
* Engaging in regular physical activity
* Limiting alcohol consumption
* Managing underlying medical conditions such as diabetes and high cholesterol.

Symptoms of influenza include:

* Fever (usually high)
* Cough
* Sore throat
* Runny or stuffy nose
* Headache
* Muscle or body aches
* Fatigue (tiredness)
* Diarrhea and nausea (more common in children than adults)

Influenza can lead to serious complications, such as pneumonia, bronchitis, and sinus and ear infections. These complications are more likely to occur in people who have a weakened immune system, such as the elderly, young children, and people with certain chronic health conditions (like heart disease, diabetes, and lung disease).

Influenza is diagnosed based on a physical examination and medical history. A healthcare provider may also use a rapid influenza test (RIT) or a polymerase chain reaction (PCR) test to confirm the diagnosis.

Treatment for influenza typically involves rest, hydration, and over-the-counter medications such as acetaminophen (Tylenol) or ibuprofen (Advil, Motrin) to relieve fever and body aches. Antiviral medications, such as oseltamivir (Tamiflu) or zanamivir (Relenza), may also be prescribed to help shorten the duration and severity of the illness. However, these medications are most effective when started within 48 hours of the onset of symptoms.

Prevention is key in avoiding influenza. Vaccination is the most effective way to prevent influenza, as well as practicing good hygiene such as washing your hands frequently, avoiding close contact with people who are sick, and staying home when you are sick.

There are several types of alcoholic liver diseases, including:

1. Alcoholic fatty liver disease (AFLD): This condition occurs when there is an accumulation of fat in the liver cells due to excessive alcohol consumption. It is the earliest stage of alcohol-related liver disease and can be reversed with abstinence from alcohol.
2. Alcoholic hepatitis (AH): This condition is characterized by inflammation of the liver, which can lead to scarring and liver failure. It is more common in individuals who consume heavy amounts of alcohol over a long period.
3. Cirrhosis: This is a chronic condition where the liver becomes scarred and cannot function properly. It is often irreversible and can lead to liver failure, heart disease, and other complications.
4. Liver failure: This is the most severe stage of alcoholic liver disease, where the liver fails to function entirely. It can be fatal if not treated promptly with a liver transplant or other medical interventions.

The symptoms of alcoholic liver disease can vary depending on the severity of the condition and may include fatigue, nausea, loss of appetite, abdominal pain, and yellowing of the skin and eyes (jaundice). Treatment for alcoholic liver disease typically involves abstinence from alcohol, medication to manage symptoms, and in severe cases, a liver transplant.

Prevention is key in avoiding alcoholic liver disease. Limiting alcohol intake, maintaining a healthy diet, and avoiding harmful substances can help reduce the risk of developing this condition. Early detection and intervention are also crucial in managing the condition before it progresses to more severe stages.

If you or someone you know is struggling with alcohol addiction, there are many resources available to help. Seeking professional assistance from a healthcare provider, therapist, or support group can provide the necessary tools and guidance to overcome alcoholism and prevent alcoholic liver disease.

The vaccine contains one of the viral envelope proteins, Hepatitis B surface antigen (HBsAg). It is produced by yeast cells, ... Hepatitis B vaccination, hepatitis B immunoglobulin, and the combination of hepatitis B vaccine plus hepatitis B immunoglobulin ... Hepatitis B, Cancer vaccines, GSK plc brands, Merck & Co. brands, Recombinant proteins, Subunit vaccines, Hepatitis vaccines, ... is a vaccine against hepatitis A and hepatitis B. Pediarix is a vaccine against diphtheria, tetanus, pertussis, hepatitis B, ...
Inactivated hepatitis A virus produced in MRC-5 cells. Each adult dose contains 1440 ELISA units of viral antigen adsorbed on ... Hepatitis A and B vaccine is a vaccine against hepatitis A and hepatitis B. Hepatitis A and typhoid vaccine is a vaccine ... Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least ... "Hepatitis A Vaccine - an overview , ScienceDirect Topics". sciencedirect.com. Retrieved 14 February 2021. "Hepatitis A Vaccine ...
Randal J (June 1999). "Hepatitis C vaccine hampered by viral complexity, many technical restraints". Journal of the National ... Although vaccines exist for hepatitis A and hepatitis B, development of an HCV vaccine has presented challenges. No vaccine is ... A hepatitis C vaccine, a vaccine capable of protecting against the hepatitis C virus (HCV), is not yet available. ... Likely, vaccines following the first approved vaccine will address other genotypes by prevalence. VLP-based HCV vaccines are ...
"Hepatitis B". www.who.int. Retrieved 2 December 2022. "Safety Information for Hepatitis B Vaccines , Vaccine Safety , CDC". www ... February 2017). "A novel hepatitis B virus subgenotype D10 circulating in Ethiopia". Journal of Viral Hepatitis. 24 (2): 163- ... Co-infection of Hepatitis B and various other viruses can also occur. Hepatitis C, Hepatitis D (a satellite virus of Hepatitis ... Hepatitis B Virus infection is easily avoided by receiving one of the Hepatitis B vaccines. The plasma-derived HepB vaccine was ...
"Protection Against Viral Hepatitis Recommendations of the Immunization Practices Advisory Committee (ACIP)". www.cdc.gov. ... Yellow fever vaccine is a vaccine that protects against yellow fever. Yellow fever is a viral infection that occurs in Africa ... Only the 17D vaccine remains in use today. Theiler's vaccine was responsible for the largest outbreak of Hepatitis B in history ... Live vaccines, Vaccines, World Health Organization essential medicines (vaccines), Yellow fever, Wikipedia medicine articles ...
E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral envelope and functions as a host ... It is a key target for the design of entry inhibitors and vaccine immunogens. Garcia JE, Puentes A, Súarez J, López R, Vera R, ... v t e (Viral structural proteins, Hepatitis C virus, All stub articles, Virus stubs). ... Bartosch B, Dubuisson J, Cosset FL (2003). "Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope ...
Kennedy, R.; Eichberg, J.; Lanford, R.; Dreesman, G. (1986). "Anti-idiotypic antibody vaccine for type B viral hepatitis in ... Kennedy has also helped to develop hepatitis B vaccines for chimpanzees and proposed their use in humans in a 1986 study. His ... Some of Kennedy's other research focused on the immune response to viral hepatitis. ... Kennedy was active in the search for an HIV vaccine for almost as long as the disease has existed. Kennedy has stated, "I first ...
Larkin M (June 24, 2020). "Adjuvanted viral-vectored vaccine promising against hepatitis C in early trial". Reuters Health News ... The Ii molecule-fused with a viral vector to a conserved region of the Hepatitis C virus (HCV) genome-has been tested as an ... June 2020). "MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans". Science ... This experimental vaccine was well-tolerated, and those who received the adjuvanted vaccine had stronger anti-HCV immune ...
... screening and control of viral hepatitis and its related diseases; Increasing hepatitis B vaccine coverage and integration into ... 2014: Hepatitis: Think Again 2015: Prevention of viral Hepatitis. Act now. 2016: Know Hepatitis-Act now. 2017: Eliminate ... Hepatitis. 2019: Invest in eliminating hepatitis. 2020: Hepatitis Free Future 2021: Hepatitis can't wait 2022: Bringing ... "World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic; 2008" ( ...
Characterisation of immunogenetics of Hepatitis C viral clearance. Irish Society of Gastroenterology Irish Society for ... Vaccine development for H. pylori infection. Immunogenetics of gastrointestinal and liver disease. In 2004, he co-founded ... Development and patenting of H. pylori vaccine, which has been licensed to Chiron Corporation. ...
He also worked on penicillin, attenuated viral vaccines, recombinant hepatitis B virus (HBV) vaccines and vaccinia viral ... After returning to China in 1950 he worked at the National Vaccine and Serum Institute (Beijing) before moving to the National ... His research on influenza viruses included work on virus structure, surveillance and subunit vaccine development. ...
A molecular biologist's view of viral hepatitis". Proceedings of the Royal Society. 230 (1259): 107-46. Bibcode:1987RSPSB.230.. ... Peptide vaccines: dream or reality?". Proceedings of the Royal Society. 344 (1308): 213-9. doi:10.1098/rstb.1994.0062. PMID ... 1985 Kenneth Murray, A molecular biologist's view of viral hepatitis 1984 William Duncan Paterson Stewart, The functional ... A prototype vaccine to prevent Epstein-Barr virus-associated tumours". Proceedings of the Royal Society. 221 (1222): 1-20. ...
Funk E, Kottilil S, Gilliam B, Talwani R (May 2014). "Tickling the TLR7 to cure viral hepatitis". Journal of Translational ... "Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration". Genetic Engineering News. August 3, ... RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B. It is an ... From antiviral formulations to vaccine adjuvants". Advanced Drug Delivery Reviews. 175: 113803. doi:10.1016/j.addr.2021.05.013 ...
A védévac előállítása diploid sejtvonalon" [Production and Control of Live Virus Vaccines" Production of Protective Vaccine on ... Simonyi's research interest were primarily with parasitology and virology of animals and she studied bovine viral diarrhea, ... canine infectious hepatitis, and swine fever. She was one of the first scientists in Hungary to detect pathogenic virus in ... The Veterinary Vaccine Control Institute, which she founded became the National Food Chain Safety Office's Directorate of ...
2011 Annual Surveillance Report of HIV, viral hepatitis, STIs Archived 22 May 2013 at the Wayback Machine (page 28) " ... The vaccine is officially called the MEL-1 vaccine but also known as the MVA-E2 vaccine. In a study it has been suggested that ... vaccines are vaccines that prevent infection by certain types of human papillomavirus (HPV). Available HPV vaccines protect ... Vaccine. 33 (29): 3422-3428. doi:10.1016/j.vaccine.2015.04.014. PMID 25869893. "HPV Vaccine and Pregnancy". eMedTV. Archived ...
Individuals with high viral loads, characteristically have ground glass hepatocytes on biopsy. Vaccines for the prevention of ... hepatitis B vaccine alone, hepatitis B immunoglobulin alone, or the combination of vaccine plus hepatitis B immunoglobulin, all ... Hepatitis B was originally known as "serum hepatitis". Acute infection with hepatitis B virus is associated with acute viral ... The hepatitis B vaccine was the first vaccine capable of preventing cancer, specifically liver cancer. Most vaccines are given ...
... hepatitis, or other chronic, viral infectious diseases with emotional, financial, and informational support. "April 2005 : ... Parents Possessing, Accessing and Communicating Knowledge about vaccines - Children's Hospital of Philadelphia". Archived from ... Green, William Finley; Hari Conjeevaram (2002). The First Year: Hepatitis B: An Essential Guide for the Newly Diagnosed. ... viral infectious diseases and educates the public on various methods of disease prevention. Founded in 1996 by a handful of ...
... also called canine hepatitis, is a DNA viral upper respiratory infection contracted through contact of a mucous membrane. ... The DA2PPC vaccine protects against the debilitating and deadly disease canine distemper. This disease is a fatal viral illness ... DA2PPC vaccine is a preventive measure against parvovirus, one of the most important diseases the vaccine protects a puppy ... This vaccine is usually given to puppies at 6-8 weeks of age, followed by 10-12 weeks of age, and then 14-16 weeks of age. This ...
... detectable hepatitis C viral RNA in Culex mosquitoes for up to 13 days. Currently, there are no specific vaccine therapies for ... There is a vaccine for yellow fever which was developed in the 1930s, the yellow 17D vaccine, and it is still in use today. The ... The viral RNA material will undergo several changes and processes inside the host's cell so that it can release more viral RNA ... The risk of complications from the vaccine are greater for individuals over 60 years of age. In addition, the vaccine is not ...
Lévy became scientific director of the vaccine programme of the French National Agency for Research on AIDS and Viral Hepatitis ... Lévy became a professor of clinical immunology, specializing on immunotherapies and vaccines for HIV infection, ... he created the Vaccine Research Institute laboratory of excellence under the Investissement d'Avenir (Investment for the Future ... retrieved 16 June 2018 Yves Lévy Vaccine Research Institute, 2016, retrieved 16 June 2018 Paul Benkimoun (June 20, 2014), Yves ...
Some diseases found associated with A1 actually link to the extended A1-B8 haplotype, viral induced hepatitis and accelerated ... A more recent paper showed an association of A*01:01 with lower than average responses to measles vaccine. With rubella, A1-B8 ... Hug G (May 1976). "Genetic factors and autoimmunity in viral hepatitis". Am. J. Clin. Pathol. 65 (5 Suppl): 870-5. PMID 218441 ...
The vaccine for hepatitis B protects against hepatitis D virus because of the latter's dependence on the presence of hepatitis ... There also have been scores of recorded cases of viral hepatitis caused by herpes simplex virus. Viral hepatitis is either ... Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with ... Effective treatments for hepatitis C are available but costly. In 2013, about 1.5 million people died from viral hepatitis, ...
International AIDS Vaccine Initiative, French National Agency for Research on AIDS and Viral Hepatitis. In June 2003, a group ... The article asserted that current attempts to develop such a vaccine were insufficient and that a renewed HIV vaccine research ... Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise (2005) The Global HIV/AIDS Vaccine Enterprise: Scientific ... 18 January 2005 Global HIV/AIDS Vaccine Enterprise (2005). "The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan ...
... dengue fever and viral hepatitis by using a proven safe vaccine virus, such as adenovirus, and modify its genome to have genes ... Another approach is to use vectors to create novel vaccines for diseases that have no vaccines available or the vaccines that ... Bull JJ, Smithson MW, Nuismer SL (January 2018). "Transmissible Viral Vaccines". Trends in Microbiology. 26 (1): 6-15. doi: ... Vaccine. 34 (50): 6436-6448. doi:10.1016/j.vaccine.2016.06.059. PMC 7115478. PMID 28029542. Gallagher, James (16 December 2012 ...
... disorders in practice Respiratory disease in practice Rheumatology in practice Thrombus Vaccines in practice Viral hepatitis in ...
MMR vaccines) and diphtheria, tetanus and pertussis (DTP) Viral Hepatitis Informatics is the science of using data, information ... Syphilis and Trichomoniasis Tuberculosis Vaccine preventable diseases, including measles, mumps and rubella ( ...
... is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral hepatitis. Many cases ... It is one of five known hepatitis viruses: A, B, C, D, and E. The hepatitis A vaccine is effective for prevention.[needs update ... World Hepatitis Day occurs each year on July 28 to bring awareness to viral hepatitis. Early symptoms of hepatovirus A ... "Hepatitis A Vaccine: What you need to know" (PDF). Vaccine Information Statement. CDC. 2006-03-21. Archived (PDF) from the ...
... the first known hepatitis with a viral etiological agent was Hepatitis A, in the picornaviridae family. Hepatitis B Virus (HBV ... was identified as an infection distinct from Hepatitis A through its contamination of measles, mumps, and yellow fever vaccines ... In replication, the viral pdsDNA is converted in the host cell nucleus to covalently-closed-circular DNA (cccDNA) by the viral ... Its best-known member is hepatitis B virus. Diseases associated with this family include: liver infections, such as hepatitis, ...
... viral hepatitis, emerging infectious diseases, vector-borne diseases, zoonotic diseases, and other contagious infectious ... Identifies, prevents, and interrupts the transmission of vaccine-preventable diseases, sexually transmitted diseases (STDs), ... and prevention of diseases caused by microbial and viral agents. Provides support to local public health laboratory personnel ... for developing and maintaining high quality local microbial and viral laboratory services, including consultation and training ...
... in countries that offered the vaccine. The HPV Prevention and Control Board is modelled on the Viral Hepatitis Prevention Board ... Since the HPV vaccines were first licensed in 2006, the Global Advisory Committee on Vaccine Safety (GACVS) have concluded that ... to address the sudden hesitancy in taking HPV vaccines in that country. Routinely given in two doses, the uptake of HPV vaccine ... The HPV vaccine was found not to be the cause of reported adverse effects and the Board contributed to efforts to regain ...
"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399-401. Bibcode: ... For example, during research to produce a more efficient vaccine for smallpox, Yasu-ichi Nagano and Yasuhiko Kojima-two ... Both hepatitis B and hepatitis C are treated with IFN-α, often in combination with other antiviral drugs. Some of those treated ... Binding of molecules uniquely found in microbes-viral glycoproteins, viral RNA, bacterial endotoxin (lipopolysaccharide), ...
HIV is a viral illness that can be transmitted sexually, by transfusion, shared needles and during child birth from mother to ... Malaria vaccines are an area of intensive research. Intestinal parasites are extremely prevalent in tropical areas. These ... hepatitis A, norovirus), and protozoa (schistosomiasis). According to UNICEF, 3,000 children die every day, worldwide due to ... It increases viral load seven to ten times, which increases the chances of transmission of HIV through sexual intercourse from ...
Research on retroviruses led to the development of a vaccine for hepatitis B, which has led to major decreases in rates of ... He took a position in 1968 as chief of the National Cancer Institute's Laboratory of Viral Carcinogenesis, staying there until ... Robert M. Chanock said the discovery "put him up there with Sabin" (creator of the oral polio vaccine) as one of the "great ... liver cancer, rates of some viral cancers, like that of the liver, have been sharply reduced. ...
He is known for his work on Q fever, and led the team that developed the first vaccine against the bacteria that causes it. ... He observed that Q fever led to a post-viral illness and hypothesised that it could cause chronic fatigue syndrome. Marmion was ... Shortly after he arrived in Edinburgh, he was involved in investigating an outbreak of hepatitis B in the local dialysis unit; ... Marmion's main research interest at this stage was Q fever; he spearheaded the development of Q-Vax, the first vaccine against ...
Viral hepatitis]. București: Editura Academiei Republicii Populare Romîne. OCLC 14659226. Nicolau, Ștefan S. (1955). Cancer și ... Levaditi, Constantin; Nicolau, Ștefan (1923). "Vaccine et néoplasmes". Annales de l'Institut Pasteur. 37 (5): 443-447. Levaditi ... The two of them published in 1922 a series of articles in which new properties of viral agents were established, including ... virusuri; cîteva considerații privitoare la ipoteza virotică a cancerului [Cancer and viruses - remarks on the cancer viral ...
Viral hepatitis is caused by five unrelated hepatotropic viruses (A-E) and may be treated with antiviral drugs depending on the ... Louis Pasteur's work in microbiology also led to the development of many vaccines for life-threatening diseases such as anthrax ... Desiccation is also largely used in the pharmaceutical industry in order to store vaccines and other products.[citation needed ... in viral respiratory tract infections. As a consequence of widespread and injudicious use of antibacterials, there has been an ...
The first virus to be used as a vaccine vector was the vaccinia virus in 1984 as a way to protect chimpanzees against hepatitis ... Viral vector based gene delivery uses a viral vector to deliver genetic material to the host cell. This is done by using a ... Viral based vectors emerged in the 1980s as a tool for transgene expression. In 1983, Albert Siegel described the use of viral ... In gene therapy a gene that is intended for delivery is packaged into a replication-deficient viral particle to form a viral ...
To create potentially protective vaccines for human pathogenic enveloped viruses for which there is currently no vaccine, it is ... Stuart, David I.; Ren, Jingshan; Wang, Xiangxi; Rao, Zihe; Fry, Elizabeth E. (May 2019). "Hepatitis A Virus Capsid Structure". ... The viral capsid is known for its protection of RNA before it is inserted into the host cell, unlike the viral envelope which ... The membrane fusion event that triggers viral entrance is caused by the viral fusion protein. Many enveloped viruses only have ...
doi:10.1002/hep.25787. PMID 22504828. S2CID 25965027. Harris SE, Martin-Ruiz C, von Zglinicki T, Starr JM, Deary IJ (July 2012 ... Two telomerase vaccines have been developed: GRNVAC1 and GV1001. GRNVAC1 isolates dendritic cells and the RNA that codes for ... viral RNA replicases and bacteriophage B-family DNA polymerases. TERT proteins from many eukaryotes have been sequenced. By ... Experimental drug and vaccine therapies targeting active telomerase have been tested in mouse models, and clinical trials have ...
One study of the genomic variation in the hepatitis C virus in patients with and without hypogammaglobulinemia found that ... Other symptoms of hypogammaglobulinemia include chronic diarrhea and complications from receiving live vaccines. Certain ... the frequency of the occurrence of genetic variation in the major viral species is reduced. They used five control patients and ... doi:10.1002/hep.510270134. PMID 9425941. S2CID 28147132. "agammaglobulinemia" at Dorland's Medical Dictionary " ...
Some Christians have objected to the use of cell cultures of some viral vaccines, and the virus of the rubella vaccine, on the ... Dubious claims about vaccines against hepatitis B, HPV and other diseases have been propagated based on misuse of data from ... Vaccine hesitancy is a delay in acceptance, or refusal, of vaccines despite the availability of vaccine services. The term ... when the routine vaccine schedule could contain more than 3,000 antigens (in a single shot of DTP vaccine). The vaccine ...
The hepatitis B vaccine prevents infection with hepatitis B virus and thus decreases the risk of liver cancer. The ... leading to the expression of viral oncogenes in the affected cell and its descendants. Replication of the data contained within ... Vaccines have been developed that prevent infection by some carcinogenic viruses. Human papillomavirus vaccine (Gardasil and ... In the developing world, 15% of cancers are due to infections such as Helicobacter pylori, hepatitis B, hepatitis C, human ...
Subunit vaccines, live attenuated vaccines. There are also new vaccine technologies such as viral vector vaccines and DNA/RNA ... cats and horses carry anti-Hepatitis E virus antibodies and thus these animals probably contribute to human Hepatitis E burden ... Pets may also serve as a reservoir of viral disease and contribute to the chronic presence of certain viral diseases in the ... There are a variety of vaccine varieties, including traditional inactivated pathogen vaccines, ...
Assessment of IgM antibodies to viral capsid antigen (a rising titer) is indicated to confirm Epstein-Barr virus or ... "Hepatic splenosis mimicking HCC in a patient with hepatitis C liver cirrhosis and mildly raised alpha feto protein; the ... a diminished response to some vaccines, and an increased susceptibility to infection. In particular, there is an increased risk ... The most common cause of acute splenomegaly in children is viral infection, which is transient and usually moderate. Basic work ...
For several vaccines (anthrax, hepatitis A, etc), the induction of detectable antibodies in blood is used as a surrogate marker ... In HIV/AIDS medicine, CD4 counts and viral loads are used as surrogate markers for drug approval for clinical trials. In ... ISBN 0-520-20233-3. Koretz, Ronald (January 13, 2015). "Is Widespread Screening for Hepatitis C Justified?". British Medical ... for vaccine effectiveness, as exposure of individuals to an actual pathogen is considered unethical. There have been a number ...
April 2010). "New genetic associations detected in a host response study to hepatitis B vaccine". Genes and Immunity. 11 (3): ... Sung PS, Hsieh SL (2019-12-06). "CLEC2 and CLEC5A: Pathogenic Host Factors in Acute Viral Infections". Frontiers in Immunology ... The researchers discovered that Japanese encephalitis virus (JEV) also binds to CLEC5A and contributes to viral pathology. With ... decreased immune cell infiltration in the lungs and improved survival compared to the wild-type mice even with comparable viral ...
The most common types are viral Hepatitis A, B, and C. Hepatitis B and C can result in chronic infections, while Hepatitis A is ... In regions where the Hepatitis vaccine is not regulated, new infections occur predominately among infant and young children. As ... "Division of Viral Hepatitis , CDC". www.cdc.gov. 2020-10-27. Retrieved 2020-11-08. "Screening for Viral Hepatitis During the ... As such, Hepatitis A is also referred to as Infectious Hepatitis, and is caused by the Hepatitis A Virus (HAV). HAV can be ...
... of the viral genome recruits viral and cellular translation factors to initiate viral protein translation. Viral proteins are ... Border Disease, which affects lambs, is also caused by Pestivirus, but has no vaccine at this time. Marker vaccines are ... "Palmitoylation of Hepatitis C Virus NS2 Regulates Its Subcellular Localization and NS2-NS3 Autocleavage". Journal of Virology. ... The bovine viral diarrhea virus (BVDV) is what causes bovine viral diarrhea (BVD). Bovine viral diarrhea virus type 1 (BVDV-1 ...
"Going Viral" campaign". HIV Medicine. 17 (3): 222-230. doi:10.1111/hiv.12364. ISSN 1468-1293. PMID 26919291. "Hepatitis C: ... She is lead investigator for the first COVID-19 vaccine trial in pregnant women. HIV Anti-retroviral Therapy: Orkin C, et al. ( ... The week-long novel campaign offered HIV, Hepatitis B and Hepatitis C testing in emergency departments around the United ... "Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency ...
They consist of short sequences that originate from viral genomes and have been incorporated into the bacterial genome. Cas ( ... Antiviral applications for therapies targeting human viruses such as HIV, herpes, and hepatitis B virus are under research. ... could lead to the manufacture of biological weapons by potential bioterrorists who might use the knowledge to create vaccine ... CRISPR associated proteins) process these sequences and cut matching viral DNA sequences. By introducing plasmids containing ...
This technique is the current standard for detecting viral infections such as AIDS and hepatitis. Once an infection has been ... which was produced in 1979 using recombinant DNA and the first genetically engineered vaccine was created in 1986 for hepatitis ... Bacterial Streptococcal pharyngitis Chlamydia Typhoid fever Tuberculosis Viral Rotavirus Hepatitis C Human papillomavirus (HPV ... "Hepatitis C". World Health Organization. Archived from the original on 2011-07-12. Retrieved 2013-04-25. Dunne EF; Unger ER; ...
August 2013). "Generation of a parvovirus B19 vaccine candidate". Vaccine. 31 (37): 3872-3878. doi:10.1016/j.vaccine.2013.06. ... The 11 kDa protein encoded by the viral genome has been implicated in viral DNA replication. The nucleotide substitution rate ... Yang SH, Lin LW, Fang YJ, Cheng AL, Kuo SH (February 2012). "Parvovirus B19 infection-related acute hepatitis after rituximab- ... There is no vaccine available for human parvovirus B19, though attempts have been made to develop one. Fifth disease or ...
It is thought that reduced bacterial and viral infections early in life direct the maturing immune system away from TH1 type ... Evidence has shown that exposure to food and fecal-oral pathogens, such as hepatitis A, Toxoplasma gondii, and Helicobacter ... after he noticed that patients who had received injections of horse serum or smallpox vaccine usually had quicker, more severe ...
Vaccine trials for JE, KFD, measles, hepatitis etc. Bangalore unit has been accredited as National Laboratory for Karnataka ... Thrust Areas in viral diseases of public health importance Identification, characterization of etiological agent of outbreaks ... Technology ready for transfer to Industry). Epidemiology and characterization of Hepatitis viruses, development of vaccines and ... Hepatitis A, B, E, Rota, Measles and Crimean Congo Hemorrhagic Fever (CCHF) viruses First visualization of Hepatitis E virus ...
The transformed cells often express permanently some viral genes. This leads to the presentation of viral antigenic peptides ... Hepatitis B (HBV) and C (HCV) viruses cause chronic inflammation which favors the appearance of hepatocarcinoma. The carcinoma ... gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma ". The New England Journal of Medicine. 364(22): ... Cancer therapy targeted at tumor antigens can involve the direct use of these antigens in vaccines, but also the adoptive ...
Cap sequences are taken from the host cell mRNA during transcription and bound to viral mRNA, this allows the viral mRNA to ... At this time, there is no vaccine for TiLV and it has an >80% mortality rate. TiLV pathology has been found to impact most the ... Ferguson HW, Kabuusu R, Beltran S, Reyes E, Lince JA, del Pozo J (June 2014). "Syncytial hepatitis of farmed tilapia, ... This acidification results in a conformational change of the viral glycoprotein, initiating membrane fusion of the viral ...
A few examples of biologics made with recombinant DNA technology include: Many vaccines are grown in tissue cultures. Viral ... Vaccines (Hepatitis B surface antigen) Monoclonal antibodies (Various) Additional products (tumour necrosis factor, therapeutic ... Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic ... or vaccines, which are usually extracted directly from a biological source. Biopharmaceutics is pharmaceutics that works with ...
Hepatitis: Improving the health of patients with viral hepatitis: Report by the Secretariat  ... Accelerating action towards a hepatitis-free future: Progress report on the regional action plan for viral hepatitis in the WHO ... Hepatitis B vaccine joins the fight against pandemic disease  Clements, C. John; Kane, M. A.; Hu, D. J.; Kim-Farley, Robert J. ... The Gambia hepatitis intervention study : follow-up of a cohort of children vaccinated against hepatitis B / J. Chotard ... [‎ ...
In the fight against viral hepatitis A, vaccines save lives. 1995. Challenge. The hepatitis A virus causes contagious, acute ... creating a vaccine against the hepatitis A virus could reduce incidence of the disease and save lives Hepatitis A FAQs for ... Developing a vaccine for all four dengue viruses 2013. *Discovering a new hepatitis C gene-and its implications for precision ... Prior to the discovery of a vaccine, an estimated 100 people died from it every year in the U.S. Hepatitis A With no treatments ...
Viral hepatitis as an occupational hazard in the health care profession. In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis ... against viral hepatitis. MMWR 1981;30:423-35. 6.Dienstag JL, Stevens CE, Bhan AK, et al. Hepatitis B vaccine administered to ... Vaccine Hepatitis B virus vaccine is a suspension of inactivated, alum-adsorbed 22-nm surface antigen particles that have been ... Vaccine Storage Vaccine should be stored at 2C-8C but not frozen. Freezing destroys the potency of the vaccine. Side Effects ...
Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653-7. DOIPubMedGoogle Scholar ... hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Samples were tested for IgG against HEV, total ... of 347 persons with reported acute jaundice syndrome cases had hepatitis E, 14% had hepatitis B, and 5% had hepatitis C (5). ... Seroprevalence for Hepatitis E and Other Viral Hepatitides among Diverse Populations, Malawi On This Page ...
immunological and virologic responses in viral hepatitis. *antiviral drug development. *HCV vaccine development ... the molecular pathogenesis of viral hepatitis, nonalcoholic fatty liver disease, autoimmune hepatitis, and noncirrhotic portal ... autoimmune hepatitis. NIH Clinical Center Hepatology Consultation Services. Under attending mentorship, fellows will perform ...
... the water we drink and the medicines and vaccines that treat and protect us. The Organization aims to provide every child, ... In Nigeria, boosting viral hepatitis awareness and treatment. 07 February 2023. Abuja - Four months before her wedding and on ... Uganda elevates health for all with free hepatitis testing, treatment and vaccines. 28 July 2023. ... Cabo Verde sets the bar for ending mother-to-child transmission of viral hepatitis 28 July 2019. ...
Notice to Readers Licensure of Inactivated Hepatitis A Vaccine and Recommendations for Use Among International Travelers ... Additional information about hepatitis A vaccine is available from CDCs Hepatitis Branch, Division of Viral and Rickettsial ... Hepatitis A vaccine can be administered simultaneously with other vaccines and toxoids -- including hepatitis B, diphtheria, ... should be vaccinated with hepatitis A vaccine or receive IG before departure. Hepatitis A vaccine at the age-appropriate dose ...
The structure of key hepatitis C virus proteins provides new insights into how the virus invades cells and could inform ... Effective vaccines against the Hepatitis C virus have proven elusive, in part because of the difficulty of deciphering the ... Viral Hepatitis: Hepatitis C (CDC). References: Structure of the hepatitis C virus E1E2 glycoprotein complex. Torrents de la ... Structure of hepatitis C proteins reveals viral vulnerabilities At a Glance. *Researchers determined the structure of key ...
Viral Hepatitis Vaccines [‎1]‎. * * Browsing Meeting reports by Subject * IRIS Home * 7. Regional Office for the Western ...
Pokorska-Śpiewak M, Marczyńska M. Pokorska-Śpiewak M, et al. Vaccines (Basel). 2023 Feb 1;11(2):330. doi: 10.3390/ ... doi: 10.1002/hep.28278. Epub 2015 Nov 13. Antiviral therapy in management of chronic hepatitis B viral infection in children: A ... doi: 10.1002/hep.28278. Epub 2015 Nov 13. Authors Maureen M Jonas 1 , Anna S F Lok 2 , Brian J McMahon 3 , Robert S Brown Jr 4 ... Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis ...
Although hepatitis B virus (HBV) classically is considered hepatotropic, it has strong lymphotropic properties as well. However ... The compartmentalization of viral variants in distinct host tissues is a frequent event in many viral infections. ... Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B ... The compartmentalization of viral variants in distinct host tissues is a frequent event in many viral infections. Although ...
Categories: Viral Hepatitis Vaccines Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) is a sterile suspension of non-infectious subunit viral vaccine derived from ... Prevention of Perinatal Hepatitis B Virus Infection with Hepatitis B Immune Globulin and Hepatitis B Vaccine, in Zuckerman, A.J ... Yeast-Recombinant Hepatitis B Vaccine, Efficacy with Hepatitis B Immune Globulin in Prevention of Perinatal Hepatitis B Virus ... RECOMBIVAX HB pediatric/adolescent vaccine 0.5 ML Injection. PSN. 5. 1658155. 0.5 ML hepatitis B surface antigen vaccine 0.01 ...
Research to Advance Vaccine Safety (R21) PA-12-038. NIAID ... National Center for HIV/AIDS, Viral Hepatitis, STD, and TB ... In addition, vaccines have contributed to significant reduction in the disease burden imposed by measles, mumps, hepatitis, ... Vaccine safety is an integral part of every aspect of vaccine development and evaluation. Despite the rigorous evaluation ... Vaccine Safety Datalink; Vaccine Adverse Events Reporting System) and to establish novel approaches to designing studies on ...
Like the hepatitis B vaccine is just a piece of protein of hepatitis B. Thats a bit more modern approach. ... Hepatitis C, we have treatments now. And I think the future is that we will have treatments for viral diseases. Better ... In the vaccine world, the traditional way to make a vaccine, there are a couple of tradition ways. In vaccines that we all get ... We actually made a, for the original SARS, we made a DNA vaccine in 2004. DNA vaccines are not very different than RNA vaccines ...
How do you get hepatitis C, that is, how is hepatitis C transmitted? Is hepatitis C contagious? Is hepatitis C curable? Learn ... about symptoms, signs, causes, and treatment for hepatitis C? ... Viral Hepatitis - Hepatitis C Information. Hepatitis C FAQs for ... There is not currently a vaccine available for Hepatitis C. There are vaccines for Hepatitis A and Hepatitis B, which are ... Viral Hepatitis - Hepatitis C Information. ,http://www.cdc.gov/hepatitis/hcv,. CDC. ...
Combined hepatitis B vaccines. Proceedings of the Viral Hepatitis Prevention Board meeting. St Julians, Malta, Viral Hepatitis ... Hepatitis B vaccine is highly immunogenic and immunization with hepatitis B vaccine in Libya showed a high response in infants ... Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine Journal, 1989, 7:106-110. ... Vaccines to prevent viral hepatitis. New England Journal of Medicine, 1997, 336:196-204. ...
Hepatitis B virus is a contagious liver infection spread from person-to-person via blood or body fluids. Who is at risk for HBV ... Prevention Tips for Hepatitis B (Hepatitis B Foundation) * Safety Information for Hepatitis B Vaccines (Centers for Disease ... What is hepatitis B?. Hepatitis B is a type of viral hepatitis. It can cause an acute (short-term) or chronic (long-term) ... FastStats: Viral Hepatitis (National Center for Health Statistics) * Viral Hepatitis Surveillance Report: United States, 2020 ( ...
Prevention of viral hepatitis in Italy.. FitzSimons D; François G; Bonanni P; Mele A; Zanetti A; Stroffolini T; Crovari P; Van ... Vaccination against hepatitis viruses in Poland.. Slusarczyk J. Vaccine; 2001 Mar; 19(17-19):2384-8. PubMed ID: 11257365. [TBL] ... 6. Viral hepatitis in Bucharest.. Paquet C; Babes VT; Drucker J; Sénémaud B; Dobrescu A. Bull World Health Organ; 1993; 71(6): ... 1. [Epidemiology of viral hepatitis].. Kaić B; Vilibić-Cavlek T; Filipović SK; Nemeth-Blazić T; Pem-Novosel I; Vucina VV; ...
To assess more adequately the immunogenicity of hepatitis B vaccine using the intradermal route, … ... The intradermal route of hepatitis B vaccine administration has been tested in several clinical trials and has produced various ... 1 Division of Viral and Rickettsial Diseases, Centers for Disease Control, Atlanta, GA 30333. ... Intradermal hepatitis B vaccination in a large hospital employee population Vaccine. 1991 Oct;9(10):723-7. doi: 10.1016/0264- ...
Hepatitis Virus Description Causes/Route of Transmission Treatment Prevention HAV Contagious, acute inflammation of the liver; ... No vaccine available.. Avoid risky behavior.. HDV. Viral infection that can damage the liver; can multiply only if HBV is ... For those uninfected, get HBV vaccine, since HDV requires HBV to multiply. For those with HBV, there is no HDV vaccine. Avoid ... Hepatitis Virus. Description. Causes/Route of Transmission. Treatment. Prevention. HAV. Contagious, acute inflammation of the ...
Active or chronic viral hepatitis. -Active or latent untreated tuberculosis. -Received Bacillus Calmette-Guerin vaccine within ... Received live attenuated vaccines within 15 weeks before the first dose. -Allergy to any component of the ustekinumab ... Active uncontrolled bacterial, viral, or fungal infection. - ...
The latest tools and data from the CDC about the viral hepatitis control program and other treatment information for public ... From CDCs Division of Viral Hepatitis. Handouts: Hepatitis B Vaccine Index-Brochures in multiple languages. From Immunization ... From the Hepatitis B Foundation. Hepatitis C. Educational Materials on Hepatitis C Co-infection. From amfAR. Hepatitis C- ... Hepatitis A. Hepatitis A Vaccine Index-Brochures in multiple languages. From Immunization Action Coalition ...
... hepatitis means inflammation of the liver. There are five main hepatitis viruses (A, B, C, D or E). Learn about the different ... How is viral hepatitis spread?. Hepatitis A and hepatitis E usually spread through contact with food or water that was ... For example, not drinking too much alcohol can prevent alcoholic hepatitis. There are vaccines to prevent hepatitis A and B. ... What causes hepatitis?. There are different types of hepatitis, with different causes:. *Viral hepatitis is the most common ...
Smallpox Vaccine [D20.215.894.899.859] * Viral Hepatitis Vaccines [D20.215.894.899.955] * Hepatitis A Vaccines [D20.215.894.899 ... Any vaccine raised against any virus or viral derivative that causes hepatitis.. Terms. Viral Hepatitis Vaccines Preferred Term ... Any vaccine raised against any virus or viral derivative that causes hepatitis.. Entry Term(s). Hepatitis, Viral, Vaccines ... Hepatitis, Viral, Animal (1977-1984). Hepatitis, Viral, Human (1977-1984). Viral Vaccines (1966-1984). Public MeSH Note. 85. ...
Seroprevalence surveys and vaccine efficacy studies;. *HIV, Hepatitis Band C viral load testing for monitoring therapy; ... Monitoring viral isolates to ensure vaccine-preventable diseases are not circulating; *Detecting viral infections of ... Supplying viral strain information and primary isolates to the Laboratory Centre for Disease Control for national viral ... Provincial viral diagnostic services; *Surveillance of respiratory, enteric and sexually transmitted infection of viral ...
ABCs of Viral Hepatitis - Sharing our stories on preparing for and responding to public health events ... Like Hepatitis A, Hepatitis B is also preventable with a vaccine. The hepatitis B virus can be passed from an infected woman to ... Tags Hepatitis A, Hepatitis B, Liver Cancer, Liver Disease, Liver Failure, Viral Hepatitis. 2 comments on "ABCs of Viral ... Hepatitis B and hepatitis C are the most common types of viral hepatitis in the United States, and can cause serious health ...
Low-level, chronic viral infections such as hepatitis delta virus in the salivary gland have been associated with the ... Immune responses of treatment-naïve patients diagnosed with Sjögrens Disease to an H1N1 influenza vaccine identified a ... Chronic inflammation following viral infections is known to lead to various autoimmune related conditions7. This has also been ... Understanding the functional role of chronic inflammation in post-viral infection sequelae. ...
... the most common types of viral hepatitis are hepatitis A, B, and C. Effective vaccines are available to help prevent hepatitis ... NHANES viral hepatitis data are used to monitor progress toward goals in Healthy People and the HHS Viral Hepatitis National ... and shipped to the Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers ... conditions until they were shipped to Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB ...
  • Clinical characterization of HEV infection is similar to that of other viral hepatitis infections, ranging from asymptomatic infection to fulminant hepatitis ( 2 ). (cdc.gov)
  • Unlike HAV and HEV, hepatitis B and C viruses (HBV and HCV) are transmitted through contact with infectious body fluids and can cause acute or chronic infection. (cdc.gov)
  • The Hepatitis C virus (HCV) is a blood-borne virus that causes liver infection. (medicinenet.com)
  • Hepatitis C infection is extremely contagious. (medicinenet.com)
  • This can occur secondary to infection with many infections, including Hepatitis C virus. (medicinenet.com)
  • Up to one-quarter of people infected with Hepatitis C will rid the virus from their bodies without treatment and not experience chronic infection. (medicinenet.com)
  • There are many new and promising medical treatments for Hepatitis C infection. (medicinenet.com)
  • The Centers for Disease Control (CDC) estimates between 2.4 million and 3.9 million people are living with chronic Hepatitis C infection. (medicinenet.com)
  • Hepatitis C infection kills more people annually than HIV/AIDS. (medicinenet.com)
  • Hepatitis C infection can be cured in certain cases. (medicinenet.com)
  • In February 1995, Havrix(R) * , an inactivated hepatitis A vaccine distributed by SmithKline Beecham Pharmaceuticals (Philadelphia, Pennsylvania) was licensed by the Food and Drug Administration for use in persons aged greater than or equal to 2 years to prevent hepatitis A virus (HAV) infection. (cdc.gov)
  • Prevaccination serologic testing may be indicated for adult travelers who probably have had prior HAV infection if the cost of testing is less than the cost of vaccination and if testing will not interfere with completion of the vaccine series. (cdc.gov)
  • Despite years of effort, researchers have not yet developed an effective vaccine that prevents infection. (nih.gov)
  • RECOMBIVAX HB is a vaccine indicated for prevention of infection caused by all known subtypes of hepatitis B virus. (nih.gov)
  • Some people with acute hepatitis B have symptoms 2 to 5 months after infection. (medlineplus.gov)
  • But if you have a chronic infection and blood tests show that hepatitis B could be damaging your liver, you may need to take antiviral medicines. (medlineplus.gov)
  • Your provider may give you a dose of the hepatitis B vaccine to prevent infection. (medlineplus.gov)
  • Active uncontrolled bacterial, viral, or fungal infection. (nih.gov)
  • Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. (nih.gov)
  • 8. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. (nih.gov)
  • This increase is believed to be related to infection with hepatitis B or hepatitis C. (cdc.gov)
  • Hepatitis A is a short-term disease caused by infection with the hepatitis A virus. (cdc.gov)
  • Hepatitis B is a liver disease that results after infection with the hepatitis B virus. (cdc.gov)
  • For instance, there are different types of drugs available to treat a wide range of liver related disorders such as antiviral drugs are utilized for treatment of hepatitis viral infection. (alliedmarketresearch.com)
  • In addition, other drugs used to cure liver related medical conditions include immunoglobulins, which are obtained from plasma of patients who have recovered from hepatitis B viral infection. (alliedmarketresearch.com)
  • People who use drugs have the right to be protected from hepatitis B infection, to know their hepatitis B status, and to have equitable and affordable access to prevention, treatment and care. (hepatitisaustralia.com)
  • Chronic infection of hepatitis B and C affects the liver overtime and causes cirrhosis and eventually liver cancer. (modernghana.com)
  • Chronic hepatitis B virus (HBV) infection can lead to substantial morbidity and mortality. (cdc.gov)
  • Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection (MMWR Recomm Rep 2008;57[No. RR-8]) regarding screening for HBV infection in the United States . (cdc.gov)
  • and persons with a history of hepatitis C virus infection. (cdc.gov)
  • Persons with chronic hepatitis B virus (HBV) infection are at increased risk for liver cancer and cirrhosis and are 70%-85% more likely to die prematurely than the general population ( 1 - 4 ). (cdc.gov)
  • To provide a framework for reaching the World Health Organization's viral hepatitis elimination goals, the Viral Hepatitis National Strategic Plan for the United States calls for an increase in the proportion of persons with HBV infection who are aware of their infection from 32% (2013-2016) to 90% by 2030 ( 12 , 13 ). (cdc.gov)
  • The three main serologic markers used to determine HBV infection status are hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) ( Table 1 ). (cdc.gov)
  • The presence of HBsAg indicates HBV infection, either acute or chronic, except when it might be transiently positive shortly after a dose of HepB vaccine ( 16 ). (cdc.gov)
  • Hepatitis B is a viral infection that attacks the liver and can cause acute and chronic disease. (case.edu)
  • Sign up for email updates from CDC's Division of Viral Hepatitis . (cdc.gov)
  • As you begin deliberations on the Fiscal Year 2015 Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, we would like to respectfully request that you allocate $47.8 million for the Division of Viral Hepatitis (DVH) at the Centers for Disease Control and Prevention (CDC), an increase of $16.4 million over the FY2014 level. (hepb.org)
  • The best way to prevent hepatitis B is to get the hepatitis B vaccine. (medlineplus.gov)
  • There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. (nih.gov)
  • There is currently no vaccine to prevent hepatitis C. Fortunately, new treatments offer a cure for most people. (cdc.gov)
  • Effective vaccines to prevent hepatitis B are available. (cdc.gov)
  • There is a vaccination against hepatitis C. (medicinenet.com)
  • Discuss the need for Hepatitis A or B vaccination with a doctor. (medicinenet.com)
  • The results suggest that intradermal vaccination with hepatitis B vaccine may be appropriate under certain conditions and for certain population subgroups. (nih.gov)
  • Decisions about when to administer an intramuscular vaccine, including RECOMBIVAX HB, to infants born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination. (nih.gov)
  • ABSTRACT The hepatitis B virus (HBV) vaccination schedule in Libya follows international recommendations (1st dose at birth, 2nd after 1 month and 3rd after 6 months). (who.int)
  • The response to HBV vaccine in 1-3-year-olds was 93.2%, but this declined with age and at 7-9 years after initial vaccination only 53.1% of children had protective titres (≥ 10 mIU/mL). (who.int)
  • RÉSUMÉ Le calendrier de vaccination contre le virus de l'hépatite B en Libye suit les recommandations internationales (première dose à la naissance, deuxième dose un mois après et troisième dose six mois après). (who.int)
  • Viral (hepatitis B virus): Both GLPLS and lichen planus have been reported to be rare events following hepatitis B virus vaccination. (medscape.com)
  • 7. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus. (nih.gov)
  • The assessment takes only five minutes and will provide personalized testing and vaccination recommendations for hepatitis A, hepatitis B, and hepatitis C. (cdc.gov)
  • Vaccines segment is expected to witness a decline owing to the fact that vaccination programs were put on hold to concentrate on medical care for COVID-19. (alliedmarketresearch.com)
  • The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. (mdpi.com)
  • The Declaration endorsed by 6th APCAT Summit further underlines: "We commit to doing everything to harness the power of our city governments to ensure that tobacco control, prevention of non-communicable diseases, TB control, elimination of viral hepatitis, routine immunization and scaling up Covid vaccination are effectively implemented and measured, along with other health and development initiatives, and the recovery from Covid is healthy, equitable and sustainable. (modernghana.com)
  • Along with Singapore, other countries like Bangladesh, Bhutan, Thailand, Malaysia, and Nepal have also successfully met the WHO target for 2020 of achieving 90% prevention of hepatitis B through vaccination (by providing birth dose of hepatitis B vaccine to newborn children). (modernghana.com)
  • Vaccination is the foundation of prevention of hepatitis B virus (HBV)" said Dr Po-Lin Chan. (modernghana.com)
  • Their new study, "Pre-Vaccination Inflammation and B-cell Signaling Predict Age-related Hyporesponse to Hepatitis B Vaccination," was published in the current issue of Nature Communications . (case.edu)
  • Vaccination is a proven approach to preventing diseases such as hepatitis B, but low age-related response caused by changes to the immune system can limit the effectiveness in the elderly. (case.edu)
  • Additionally, hepatitis A vaccination is recommended for person considered at high risk for developing hepatitis A related to travel, employment, pre-existing health issues, lifestyle and in the event of an outbreak situation. (nvic.org)
  • NVIC encourages you to become fully informed about Hepatitis A and the Hepatitis A vaccine by reading all sections in the Table of Contents below, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. (nvic.org)
  • The National Hepatitis B Strategy 2023-2030 and the National Hepatitis C Strategy 2023-2030 (the Strategies) have been released for public consultation by the Department of Health and Aged Care. (hepatitisaustralia.com)
  • The International HIV Coinfection + Viral Hepatitis Elimination Conference will be taking place in Brisbane, Australia ahead of IAS 2023. (hepatitisaustralia.com)
  • On May 11, 2023, Action Hepatitis Canada (AHC) released its Progress Toward Viral Hepatitis Elimination in Canada 2023 Report . (catie.ca)
  • We updated them for the 2023 report to include hepatitis B metrics and to more closely align with the WHO targets, as these were included in the pan-Canadian framework for action , as well as the Canadian government's five-year action plan , which was endorsed by all provinces and territories. (catie.ca)
  • The hepatitis A virus causes contagious, acute inflammation of the liver. (nih.gov)
  • 1973). Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness . (nih.gov)
  • In northern Uganda, surveillance of health care facilities during 2010-2012 showed that 42% of 347 persons with reported acute jaundice syndrome cases had hepatitis E, 14% had hepatitis B, and 5% had hepatitis C ( 5 ). (cdc.gov)
  • An estimated 30,500 acute hepatitis C cases occurred in 2014. (medicinenet.com)
  • In rare cases, acute hepatitis B can cause liver failure. (medlineplus.gov)
  • If you have acute hepatitis B, you probably don't need treatment. (medlineplus.gov)
  • Some types of hepatitis cause only acute infections. (nih.gov)
  • Treatment for hepatitis depends on which type you have and whether it is acute or chronic. (nih.gov)
  • Acute viral hepatitis often goes away on its own. (nih.gov)
  • The Advisory Committee on Immunization Practices (ACIP) offers the following interim recommendations for the use of inactivated hepatitis A vaccine among international travelers. (cdc.gov)
  • 17. Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. (nih.gov)
  • Moreover, liver diseases also include use of vaccines to provide immunization against viral hepatitis. (alliedmarketresearch.com)
  • For instance, vaccines suffered a negative impact as immunization programs were halted. (alliedmarketresearch.com)
  • These changes may play a role in immunization failure, but other factors including viral load may be more important. (deepdyve.com)
  • HBV, immunization, HBsAg mutants, vaccine escape, viral load, infected infants Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) represents an important mechanism for the generation and maintenance of persistent infections within populations. (deepdyve.com)
  • The World Health Organization's recommendation for national HBV immunization programs worldwide is aimed at eliminating perinatal transmission through active HBV immunization within 24 hours of birth with the addition of hepatitis B immune globulin (HBIG) where there is a high risk of transmission [2]. (deepdyve.com)
  • The U.S. Food and Drug Administration and U.S. Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control (CDC) has approved three different hepatitis A containing shots. (nvic.org)
  • The CDC's Advisory Committee on Immunization Practices currently recommends that all children receive the first dose of hepatitis A vaccine between 12 and 23 months of age and the second dose is recommended 6 months or longer following the first dose of the vaccine. (nvic.org)
  • Often, people with hepatitis B don't have symptoms. (medlineplus.gov)
  • Some people with hepatitis do not have symptoms and do not know they are infected. (nih.gov)
  • Once diagnosed, most people with hepatitis C can be cured in just 8 to 12 weeks, which reduces their risk for liver cancer. (cdc.gov)
  • Asia and the Pacific has more than half of world's total number of people with hepatitis B and C virus. (modernghana.com)
  • IRP researchers Robert Purcell, M.D. , Albert Kapikian, M.D. , Stephen Feinstone, M.D., and colleagues played a crucial role in developing the first licensed hepatitis A vaccine, from initial identification and characterization of the virus to the clinical trials that demonstrated protective efficacy a glimpse of history . (nih.gov)
  • Based on a controlled clinical trial, the efficacy of two doses of vaccine (360 enzyme-linked immunosorbent assay units) administered 1 month apart in preventing hepatitis A in children was estimated to be 94% (95% confidence interval=79%-99%) (3). (cdc.gov)
  • Despite these drawbacks, some nucleoside analogues have been found efficacious against hepatitis B virus and it is likely that as knowledge of their mechanism of action accumulates, their efficacy can be improved both by rational drug design and by use in combination with other drugs, including interferon. (edu.au)
  • Continued monitoring of vaccine efficacy is essential. (deepdyve.com)
  • Immunogenicity studies have indicated that virtually 100% of children, adolescents, and adults develop protective levels of antibody to hepatitis A virus (anti-HAV) after completing the vaccine series (1,2). (cdc.gov)
  • When immune globulin (IG) is given concurrently with the first dose of vaccine, the proportion of persons who develop protective levels of anti-HAV is not affected, but antibody concentrations are lower. (cdc.gov)
  • Viral hepatitis, type B, DNA polymerase activity and antibody to hepatitis B core antigen. (nih.gov)
  • No significant differences between males and females in antibody persistence or response to vaccine were observed. (who.int)
  • 1999. Viral persistence, antibody to e1 and e2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. (nationalacademies.org)
  • a combination vaccine containing both inactivated hepatitis A virus vaccine (HAVRIX) and recombinant hepatitis B vaccine (ENGERIX-B), manufactured by GlaxoSmithKline. (nvic.org)
  • Serum levels of hepatitis B surface antigen were determined in 277 randomly selected children aged 1-12 years. (who.int)
  • Sequencing and epitope phenotyping were used to investigate alterations in hepatitis B surface antigen (HBsAg) sequence and antigenicity in infants and in mothers known to have transmitted and not to have transmitted virus to their infants. (deepdyve.com)
  • Optimally implemented, these actions have had a dramatic impact on reducing MTCT, with an 87% reduction observed in the seroprevalence of hepatitis B surface antigen (HBsAg) in children in countries of previous high endemicity [3]. (deepdyve.com)
  • 1 Division of Viral and Rickettsial Diseases, Centers for Disease Control, Atlanta, GA 30333. (nih.gov)
  • To assess more adequately the immunogenicity of hepatitis B vaccine using the intradermal route, the Centers for Disease Control conducted a clinical trial among 425 well health-care workers in a hospital setting. (nih.gov)
  • 15. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. (nih.gov)
  • Elimination of viral hepatitis should be part of any sound public health agenda. (modernghana.com)
  • The Mayors and other subnational leaders and delegates of APCAT Summit adopted an APCAT Declaration 2021 which includes the promise for "addressing the challenge of viral hepatitis as a major public health threat in the Asia Pacific region through elimination of mother to child transmission by raising public awareness and strengthening health systems through public and private partnerships. (modernghana.com)
  • Dr Po-Lin Chan from Manila-based World Health Organization (WHO)'s Western Pacific regional office said that "Elimination of viral hepatitis as a public health threat by 2030 is a combination of existing interventions at scale. (modernghana.com)
  • These barriers to achieving viral hepatitis elimination will remain if we do not take a reconciliatory approach to healthcare for Indigenous people, and address inequities in healthcare access for people living in remote and rural areas, as well as for those structurally excluded from mainstream healthcare and society more broadly. (catie.ca)
  • Each jurisdiction must create and implement its own strategy toward viral hepatitis elimination. (catie.ca)
  • Today's date is Monday, March 21, 2022, and I am speaking with Dr. John Mascola for the Vaccine Research Center with the National Institute of Allergies and Infectious Diseases, which is part of the National Institutes of Health, or NIH. (nih.gov)
  • Dr. Mascola is the director of the Dale and Betty Bumpers Vaccine Research Center, or VRC, at the National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health. (nih.gov)
  • So, I'm quite sure that seeing the first early AIDS patients who did not do well and seeing a viral disease that could destroy the immune system without a clear understanding of what was happening or how to benefit those patients really inspired me toward a career in infectious diseases, and, more specifically, towards a research career in viral immunology. (nih.gov)
  • Surveillance and diagnostic testing in support of Public Health Programs, e.g. prenatal screening for HIV, Syphilis, Hepatitis Band immune status testing for Rubella;Serodiagnostic testing for viral, bacterial and parasitic diseases, e.g. (gov.mb.ca)
  • Liver disease treatments are defined as any medical care provided to the patient suffering from liver diseases in form of vaccines and drugs. (alliedmarketresearch.com)
  • Hepatitis B (HB) and C (HC) are two severe viral infectious diseases with a deleterious impact on global health. (biomedcentral.com)
  • No mRNA vaccine has been approved for use in any disease, although some are in clinical trials for other diseases. (melvinkonner.com)
  • In some cases, your provider may also give you a medicine called hepatitis B immune globulin (HBIG). (medlineplus.gov)
  • Results Vaccine/hepatitis B immune globulin uptake was complete in the majority of HBV-infected infants. (deepdyve.com)
  • Prior to the discovery of a vaccine, an estimated 100 people died from it every year in the U.S. Hepatitis A With no treatments, creating a vaccine against the hepatitis A virus could reduce incidence of the disease and save lives Hepatitis A FAQs for Health Professionals . (nih.gov)
  • 1981). Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage . (nih.gov)
  • Worldwide, recommendations for using hepatitis B virus (HBV) vaccine will vary in accordance with local patterns of HBV transmission. (cdc.gov)
  • Data on prevalence of hepatitis E virus (HEV) in Malawi is limited. (cdc.gov)
  • We tested blood samples from HIV-uninfected and -infected populations of women and men enrolled in research studies in Malawi during 1989-2008 to determine the seroprevalence of HEV, hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV). (cdc.gov)
  • Hepatitis E virus (HEV) is primarily a waterborne virus that is transmitted by the fecal-oral route. (cdc.gov)
  • Most people (up to 80%) infected with Hepatitis C virus do not have any symptoms in the beginning. (medicinenet.com)
  • Hepatitis C virus is curable. (medicinenet.com)
  • Researchers determined the structure of key hepatitis C virus proteins bound to three neutralizing antibodies. (nih.gov)
  • Effective vaccines against the Hepatitis C virus have proven elusive, in part because of the difficulty of deciphering the structures on its surface. (nih.gov)
  • This long sought-after structural information on hepatitis C virus puts a wealth of previous observations into a structural context and paves the way for rational vaccine design against this incredibly difficult target," Ward says. (nih.gov)
  • Structure of the hepatitis C virus E1E2 glycoprotein complex. (nih.gov)
  • Hepatitis B is caused by the hepatitis B virus. (medlineplus.gov)
  • If you have ever had hepatitis B, the virus may become active again, or reactivated, later in life. (medlineplus.gov)
  • If you think you have been in contact with the hepatitis B virus, see your health care provider right away. (medlineplus.gov)
  • You need to get the vaccine and the HBIG (if needed) as soon as possible after coming into contact with the virus. (medlineplus.gov)
  • Doctors treat hepatitis C with antiviral medicines that attack the virus and can cure the disease in most cases. (nih.gov)
  • The hepatitis B virus vaccine is hypothesized to stimulate the immune system and trigger lichen planus eruptions in a nonspecific manner. (medscape.com)
  • 2. T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. (nih.gov)
  • 5. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus. (nih.gov)
  • 9. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV. (nih.gov)
  • 10. Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. (nih.gov)
  • 11. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice. (nih.gov)
  • 12. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. (nih.gov)
  • 13. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. (nih.gov)
  • 14. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. (nih.gov)
  • 16. Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells. (nih.gov)
  • Any vaccine raised against any virus or viral derivative that causes hepatitis. (nih.gov)
  • Viral hepatitis is the term that describes inflammation of the liver that is caused by a virus. (cdc.gov)
  • Hepatitis A is usually spread when a person ingests the virus from contact with objects, food, or drinks contaminated by solid waste from an infected person. (cdc.gov)
  • The hepatitis B virus can be passed from an infected woman to her baby at birth, if her baby does not receive the hepatitis B vaccine. (cdc.gov)
  • However, widespread screening of the blood supply in the United States began in 1990.The hepatitis C virus was virtually eliminated from the blood supply by 1992. (cdc.gov)
  • 1998. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. (nationalacademies.org)
  • World Health Organization (WHO) statistics reported 240 million people contaminated with hepatitis B virus (HBV) in 2016 with HBsAg-positive test for at least 6 months [ 2 ]. (biomedcentral.com)
  • The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. (mdpi.com)
  • Despite over 350 million people living with hepatitis B and C virus globally, and 3 persons dying every minute, much-needed efforts are yet to be on-track to end viral hepatitis in next 108 months (by 2030) as promised by heads of all countries in UN General Assembly (by adopting the Sustainable Development Goals). (modernghana.com)
  • Globally, 296 million people are estimated to be infected with Hepatitis B Virus (HBV), and 58 million with Hepatitis C Virus (HCV). (modernghana.com)
  • The use of nucleoside analogues against the agents of viral hepatitis is inherently problematic for many reasons including active hepatic nucleoside catabolism, probable absence of virus-specific activating enzymes, competition from endogenous nucleotides synthesised de novo or derived from RNA turnover, and factors related to mitochondrial toxicity. (edu.au)
  • In the study, hepatitis B virus-naïve older adults received three vaccines, including one against HBV. (case.edu)
  • Three of the 5 are viral vector vaccines, which use a partly disabled different virus to deliver coronavirus genes into cells, to make the surface proteins that provoke the immune response. (melvinkonner.com)
  • Hepatitis A is viral disease of the liver caused by the hepatitis A virus (HAV). (nvic.org)
  • The hepatitis A virus is very stable and can remain present for several months in most environments. (nvic.org)
  • Symptoms of hepatitis A generally appear between two and seven weeks following exposure to the virus and infected individuals can spread the virus to others for up to two weeks before showing symptoms. (nvic.org)
  • Australia antigen and hepatitis in renal units. (nih.gov)
  • Informed by HIV self-testing success and community-wide acceptance and uptake of COVID-19 (rapid antigen tests - RATs) self-testing, there is a growing momentum internationally and in Australia behind self-testing for hepatitis C as part of a broader suite of testing approaches and strategies. (hepatitisaustralia.com)
  • Hepatitis C RNA or antigen reflex testing implemented? (catie.ca)
  • More than 400 million people are infected with hepatitis B or C worldwide. (gatewaygazette.ca)
  • The CDC's 2010 professional judgment (PJ) budget recommended $90.8 million each year from FY2011-FY2013, $170.3 million annually from FY2014-FY2017, and $306.3 million annually from FY2018-FY2020 for DVH in order to comprehensively address the viral hepatitis epidemic. (hepb.org)
  • Our recommendation of $47.8 million is in line with the needs determined by the PJ and the goals of the Viral Hepatitis Action Plan , but pales in comparison to the CDC's PJ. (hepb.org)
  • Hepatitis A is easily prevented with a safe and effective vaccine, which is believed to have caused the dramatic decline in new cases in recent years. (cdc.gov)
  • This principle has yielded an effective vaccine for Ebola and an ineffective one for HIV. (melvinkonner.com)
  • Hepatitis A vaccine at the age-appropriate dose Table 1 is preferred for persons who plan to travel repeatedly to or reside for long periods in these high-risk areas. (cdc.gov)
  • After receiving the initial dose of hepatitis A vaccine, persons are considered to be protected by 4 weeks. (cdc.gov)
  • For persons who will travel to high-risk areas less than 4 weeks after the initial vaccine dose, IG (0.02 mL per kg of body weight) should be administered simultaneously with the first dose of vaccine but at different injection sites. (cdc.gov)
  • Persons who are allergic to a vaccine component or otherwise elect not to receive vaccine should receive a single dose of IG (0.02 mL per kg of body weight), which provides effective protection against hepatitis A for up to 3 months. (cdc.gov)
  • Participants received the plasma-derived hepatitis B vaccine by the standard schedule at 0, 1 and 6 months, and serum samples were collected at 3, 8, 12 and 24 months after the first dose. (nih.gov)
  • Received live attenuated vaccines within 15 weeks before the first dose. (nih.gov)
  • Transcriptome analyses indicated that MAVS deficiency negatively affected the induction of early anti-viral responses, which resulted in significantly increased TBEV replication. (stanford.edu)
  • The researchers found that heightened expression of genes that augment B-cell responses and higher memory B-cell frequencies correlated with stronger responses to the hepatitis B vaccine. (case.edu)
  • In contrast, higher levels of inflammatory response transcripts and increased frequencies of pro-inflammatory innate cells correlated with weaker responses to this vaccine. (case.edu)
  • 2005). Prevention of hepatitis A by Havrix: a review . (nih.gov)
  • However, if precautions are not followed then transmission of hepatitis C and other infections may be possible. (medicinenet.com)
  • Hepatitis C is one of the most common blood-borne infections in the United States. (nih.gov)
  • Considering the importance of HB and HC, the present study aimed to estimate the prevalence of these viral infections among the PERSIAN Guilan cohort study (PGCS) participants. (biomedcentral.com)
  • To characterize the biochemical and immunological properties of an experimental ISCOMS vaccine prepared from a novel therapeutic polypeptide based on T cell epitopes of HBsAg, and a heptatis B-ISCOMS was prepared and investigated. (wjgnet.com)
  • The World Health Organization estimates 325 million people worldwide are living with chronic hepatitis B or chronic hepatitis C. In 2015, 1.34 million died from viral hepatitis , a number that is almost equal to the number of deaths caused by tuberculosis and HIV combined. (cdc.gov)
  • According to the World Health Organization, an estimated 240 million people are chronically infected with hepatitis B and more than 780,000 people die every year due to complications of hepatitis B, including cirrhosis and liver cancer. (case.edu)
  • This is an update on the 2021 report and provides an analysis of each province and territory's progress toward eliminating viral hepatitis as a public health threat by 2030, a goal set by the World Health Organization (WHO). (catie.ca)
  • Where to go for the ABCs of viral hepatitis prevention? (cdc.gov)
  • There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine. (case.edu)
  • No clear trends over time were observed in the seroprevalence of HEV, and HIV status was not associated with hepatitis seroprevalence. (cdc.gov)
  • Experimental Treatments and Preventive Therapies for HIV, Hepatitis C, and Tuberculosis: By Mark Harrington, Bob Huff, and Richard Jefferys. (treatmentactiongroup.org)
  • Viral hepatitis is an essential part of the #HealthForAll agenda", said Dr Tara Singh Bam, Asia Pacific Director of the International Union Against Tuberculosis and Lung Disease (The Union), and Board Director of Asia Pacific Cities Alliance for Health and Development (APCAT) in Singapore. (modernghana.com)
  • With a cure for hepatitis C and a vaccine for hepatitis B, this is an ambitious yet realistic goal. (catie.ca)
  • The complete ACIP recommendations for the prevention of hepatitis A will be published. (cdc.gov)
  • People who drink a lot over long periods of time are at risk for alcoholic hepatitis. (nih.gov)
  • People who have alcoholic hepatitis need to stop drinking. (nih.gov)
  • For example, not drinking too much alcohol can prevent alcoholic hepatitis. (nih.gov)
  • Similarly, drugs such as corticosteroids are used in treatment of alcoholic hepatitis and immunosuppressants are administered to patients with a transplanted liver. (alliedmarketresearch.com)
  • The risks are different for the different types of hepatitis. (nih.gov)
  • There are different medicines to treat the different chronic types of hepatitis. (nih.gov)
  • Who is at risk for hepatitis B? (medlineplus.gov)
  • There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. (nih.gov)
  • Following three big days of inspiring presentations and reconnecting with many in the sector, Hepatitis Australia and the Australasian Society for HIV, Viral Hepatitis & Sexual Health Medicines (ASHM) launched the VH2022 Action Plan. (hepatitisaustralia.com)
  • If you have chronic hepatitis B, you may not have symptoms until complications develop. (medlineplus.gov)
  • Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer . (nih.gov)
  • Early diagnosis and treatment of chronic hepatitis may prevent these complications. (nih.gov)
  • All these premature deaths are untimely and so preventable, because we have prevention tools, as well as good tests and drugs that can treat hepatitis B and C, and hepatitis C can be cured. (modernghana.com)
  • Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. (nih.gov)
  • As a result, the hepatitis B vaccine is recommended for all infants at birth. (cdc.gov)
  • There is not currently a vaccine available for Hepatitis C. There are vaccines for Hepatitis A and Hepatitis B, which are different viruses that can also affect the liver. (medicinenet.com)
  • It is caused by one of several viruses -- hepatitis viruses A , B , C , D, and E. In the United States, A, B, and C are the most common. (nih.gov)
  • The most common types of viral hepatitis are A, B and C. These three viruses affect millions of people worldwide, causing both short-term illness and long-term liver disease. (cdc.gov)
  • The real-time PCR assay was employed to quantify the gene copies of hepatitis B and C viruses. (biomedcentral.com)
  • Hepatitis B and C are the most common blood borne viruses in Australia but testing for them is not part of normal blood tests-you generally have to ask your doctor. (hepatitisaustralia.com)
  • Cleveland, OH - January 20, 2016 - Physicians have known for years that patients respond differently to vaccines as they age. (case.edu)
  • Today, most people become infected with hepatitis C by sharing needles, syringes, or any other equipment to inject drugs. (cdc.gov)
  • Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. (edu.au)
  • The discovery and development of hepatitis A vaccines were landmark moments for public health, providing nearly 100 percent of adults with protective levels of antibodies, and contributing to the decline of hepatitis A rates in the U.S. by 92 percent since 1995 Hepatitis A FAQs for Health Professionals . (nih.gov)
  • Hepatitis B is common in many parts of the world, including Asia, the Pacific Islands and Africa. (cdc.gov)
  • Hepatitis C is a leading cause of long-term liver disease and liver cancer. (nih.gov)
  • Chronic active hepatitis develops in over 25% of carriers (100,000-200,000), and often progresses to cirrhosis. (cdc.gov)
  • It is estimated that 4,000 persons die from hepatitis B-related cirrhosis each year in this country, and that more than 800 die from hepatitis B-related liver cancer. (cdc.gov)
  • Most recently, both the NIH Director's Award for outstanding efforts leading to successful development of Covid vaccines and therapeutics and a presidential commendation for Covid-19 vaccine development, Operation Warp Speed. (nih.gov)
  • It is not clear what criteria were used to choose those 5, but it is likely that the name "Warp Speed" will increase the number of vaccine refusers. (melvinkonner.com)
  • There are about ___________ Americans living with chronic hepatitis C. (medicinenet.com)
  • Some people with chronic hepatitis B will need treatment. (medlineplus.gov)
  • However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C restrict the market growth. (alliedmarketresearch.com)
  • Health+Law is a research partnership to identify and eliminate legal barriers to testing and treatment for people living with Hepatitis B or HIV in Australia. (hepatitisaustralia.com)
  • The Motivate C project, led by the University of Sydney, is studying whether the offer of a cash incentive will encourage people to take up hepatitis C treatment in primary care. (hepatitisaustralia.com)
  • Viral hepatitis affects a number of populations that have been historically marginalized by mainstream healthcare, creating hurdles to equitable prevention, testing and treatment services. (catie.ca)